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                 “All our knowledge begins with the senses, proceeds then to the understanding, 
and ends with reason. There is nothing higher than reason.” 
—Immanuel Kant (1724–1804) 
 
  
ABSTRACT 
Background: Parkinson’s disease (PD) is a neurodegenerative disease characterized by rigidity, hypokinesia, 
tremor and postural instability. PD is a clinical diagnosis based on neurological examination, patient history and 
treatment response. Similar symptoms can be caused by other movement disorders such as progressive 
supranuclear palsy (PSP) and multiple system atrophy (MSA), making it difficult to clinically separate them in 
early stages. However, these diseases differ in underlying pathology, treatment and prognosis. PSP and MSA have 
more rapid deterioration and develop additional symptoms such as impaired eye movements or autonomic 
dysfunction. Magnetic resonance imaging (MRI) is commonly performed as part of the clinical work-up in patients 
presenting with parkinsonism. There are no overt changes on structural MRI in PD. In atypical parkinsonian 
syndromes there are typically no visible changes until later disease stages.  
Purpose: The aim of this thesis is to evaluate novel MRI techniques for diagnostics and for investigation of disease 
processes in Parkinson’s disease, PSP and MSA. 
Paper I: A retrospective cohort from Karolinska University Hospital (102 participants; 62 PD, 15 PSP, 11 MSA, 
14 controls) was assessed using susceptibility mapping processed from susceptibility weighted imaging. We show 
that there is elevated susceptibility in the red nucleus and the globus pallidus in PSP compared to PD, MSA and 
controls. Higher susceptibility levels were also seen in MSA compared to PD in the putamen, and in PD compared 
to controls in the substantia nigra. Using the red nucleus susceptibility as a diagnostic biomarker, PSP could be 
separated from PD with an accuracy of 97% (based on the area under the receiver operating characteristic curve, 
AUC), from MSA with AUC 75% and from controls with AUC 98%. We concluded that susceptibility changes, 
particularly in the red nucleus in PSP, could be potential biomarkers for differential diagnostics in parkinsonism.  
Paper II: A prospective cohort from Lund, the BioFINDER study (199 participants; 134 PD, 11 PSP, 10 MSA, 
44 controls), was investigated using the susceptibility mapping pipeline developed for Paper I. The finding from 
Paper I with elevated susceptibility in the red nucleus was validated for PSP compared to PD, MSA and controls. 
The elevated putaminal susceptibility was also confirmed in MSA compared to PD. The potential role of red 
nucleus susceptibility as a biomarker for separating PSP from PD and MSA was also similar to the results in Paper 
I, with AUC 98% for separating PSP from PD and AUC 96% for separating PSP from MSA. We concluded that 
we could confirm our previous findings from Paper I, with the red nucleus susceptibility being a potential 
biomarker for separating PSP from PD and MSA. 
Paper III: A retrospective cohort from Karolinska University Hospital (196 participants; 140 PD, 29 PSP, 27 
MSA) was evaluated to employ automated volumetric brainstem segmentation using FreeSurfer. The volumetric 
approach was compared to manual planimetric measurements: midbrain-pons ratio, magnetic resonance 
parkinsonism index 1.0 and 2.0. Intra- and inter-scanner as well as intra- and inter-rater reliability were calculated. 
We found good repeatability in both automated volumetric and manual planimetric measurements. Normalized 
midbrain volume performed better than the planimetric measurements for separating PSP from PD. We concluded 
that, if further developed and incorporated in a radiology workflow, automated brainstem volumetry could increase 
availability of brainstem metrics and possibly save time for radiologists conducting manual measurements. 
Paper IV: Two cohorts, a retrospective from Karolinska University Hospital (184 participants; 129 PD, 28 PSP, 
27 MSA) and a prospective from Lund (185 participants; 125 PD, 11 PSP, 8 MSA, 41 controls), were studied to 
investigate a new method of creating T1-/T2-weighted ratio images and its diagnostic capabilities in differentiating 
parkinsonian disorders. In the explorative retrospective cohort, differences in white matter normalized T1-/T2-
weighted ratios were seen in the caudate nucleus, putamen, thalamus, subthalamic nucleus and red nucleus in PSP 
compared to PD; in the caudate nucleus and putamen in MSA compared to PD and in the subthalamic nucleus and 
the red nucleus in PSP compared to MSA. These differences were validated externally in the prospective cohort, 
where the changes could be confirmed in the subthalamic nucleus and the red nucleus in PSP compared to PD and 
MSA. We concluded that there are different patterns of white matter normalized T1-/T2-weighted ratio between 
the disorders and that this reflects differences in underlying pathophysiology. The T1-/T2-weighted ratio should be 
further investigated for better understanding of pathological processes in parkinsonian disorders and could possibly 
be utilized for diagnostic purposes if further developed. 
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1 INTRODUCTION 
1.1 PARKINSON’S DISEASE 
1.1.1 Background 
When James Parkinson (1775–1824) published his renowned “An Essay on the Shaking Palsy” 
in 1817,1 he gave a coherent and thoughtful description of a disease that was up until then 
overlooked and practically unknown. In this essay based on his keen observations of patients 
he probably had close contact with, as well as cases he met on the street, he describes the 
symptoms and traits of what was later to be known as Parkinson’s disease (PD). He also refers 
back to earlier writings of Sylvius de la Boë and Boissier de Sauvages. The former describing 
the separation of tremors occurring during action from tremors occurring at rest (‘tremor 
coactus’). De Sauvages notes that this form of tremor at rest can be observed as a leaping of 
the body part even when supported, whereas other forms of tremor ceases when movements 
stop, but returns when the limb moves again. He also describes a variant of ‘scelotyrbe’ 
(meaning weakness) called ‘scelotyrbe festinans’ (festinans meaning hastening), where 
patients trying to walk are instead forced to run. James Parkinson acknowledges that these two 
symptoms, the ‘tremor coactus’ (resting tremor) and the ‘scelotyrbe festinans’ together with 
the tendency to bend the trunk forwards, are the pathognomonic symptoms of the shaking 
palsy. 
One person who brought more attention to this disorder, and also acknowledged the work of 
James Parkinson, was the famous neurologist Jean-Martin Charcot. He was also the one 
suggesting that the disorder should be referred to as Parkinson’s disease.2 He also expanded 
the description and identified rigidity and bradykinesia as the core features of the disorder and 
that while the resting tremor was common, it was not an obligatory feature. Charcot also noted 
that the patients were not distinctly weak, and that the term palsy should therefore be avoided. 
1.1.2 Epidemiology 
PD is the second most common neurodegenerative disease world-wide. Globally, over 6 
million individuals are affected by this disease.3 It is also the fastest growing neurological 
disorder included in Global Burden of Disease 2015 study. Age is the greatest risk factor, and 
PD is 40% more common in males than in females in most populations.3,4 It has also been 
found that the incidence is greater in individuals exposed to pesticides and traumatic brain 
injury.5 Smoking and caffeine, on the other hand, seem to be associated with a lower incidence 
of PD.4 Whether smoking truly is protective or not has been debated, and it has also been shown 
that individuals with PD are able to quit smoking more easily than controls.6 A map of global 
age-standardized prevalence of PD is shown in Figure 1.3 
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The global differences in age-standardized prevalence are not fully understood but may be due 
to a combination of methodology of the different underlying prevalence studies, differences in 
disease awareness, but also possible differences in risk factors as well as due to genetic factors. 
As stated above, the main risk factor is age. As seen in Figure 2, there is a marked increase in 
the prevalence of PD in both male and female with increasing age. PD is globally a major cause 
of death and disability, and caused 211 296 deaths and 3.2 million disability-adjusted life-years 
in 2016.3 
 
Concerning genetics, mutations in several different genes have been found to cause familial 
PD with autosomal dominant inheritance patterns shown for mutations or duplication in the 
alpha-synuclein gene, ubiquitin C-terminal hydrolase L1 and leucine rich repeat kinase 2 
(LRRK2), among others.7 Other genes found to cause an autosomal recessive inheritance 
pattern include parkin RBR E3 ubiquitin protein ligase and PTEN induced putative kinase 1 
(PINK1). 
While there are many known genetic mutations associated with familial PD, it has also been 
found that certain mutations increase the risk of developing the disease. Such identified genes 
associated with increased risk of developing PD are glucocerebrocidase (GBA) and MAPT.7 
Recently, much attention has been focused on mutations in the GBA gene, which were first 
described in patients with Gaucher’s disease. Gaucher’s disease is an autosomal recessive 
lysosomal storage disorder in which glucocerebroside is accumulated in multiple organs, bone 
and neural systems.8 Mutations in the GBA gene have been implicated as risk factors for PD, 
and shown to be present in 4-10% of patients with PD as opposed to 0.4-1.0% reported in 
 4 
healthy controls.9 A possible mechanism is thought to be that the loss of glucocerebrosidase 
function impairs lysosomal activity and leads to accumulation of a-synuclein.7 It should also 
be noted that the distinction between disease-causing genes and genes conveying an increased 
risk of disease is not always easily discernible, or even possible. 
1.1.3 Etiology 
PD is a neurodegenerative movement disorder. The core pathological feature in PD is the loss 
of dopaminergic neurons in the substantia nigra pars compacta in the midbrain.5 This region 
contains neurons projecting unmyelinated axons mainly to the ipsilateral dorsal striatum. It has 
also been shown to occur neuronal loss in additional brain regions such as the locus coeruleus, 
raphe nucleus and the dorsal motor nucleus of the vagus nerve.5 
Another important pathological feature of PD is the accumulation and aggregation of misfolded 
alpha-synuclein in both intra-cellular inclusions and in neurites, Lewy bodies and Lewy 
neurites respectively.4,5 Lewy pathology has been found in practically all neuronal tissues 
including the brain, peripheral nervous system, spinal cord and adrenal glands.5 Examples of 
Lewy bodies and Lewy neurites are shown in Figure 3. 
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It has been hypothesized that the disease process initiates peripherally and then spreads in a 
caudal-to-rostral fashion.10 This might in part explain the typical progression of symptoms 
commonly beginning with non-motor symptoms such as constipation and loss of the sense of 
smell, and then gradually moving higher to affect regulation of movements and lastly cortical 
functions. This model of disease progression was first proposed by the neuropathologist Heiko 
Braak and is commonly referred to as the Braak model.10 A schematic depiction of this model 
is given in Figure 4.11 This model has been debated and there are proponents of both the gut-
first and the brain-first models on the pathogenesis of PD. 
 
 
Iron in Parkinson’s disease 
It has been shown that there is an abnormal accumulation of iron in the substantia nigra in 
PD.12–14 Coupled to this, there is a significant increase of ferritin, which binds Fe3+, and a shift 
in the relationship of Fe2+ and Fe3+ in favor of the latter.14,15 Neuromelanin, which is a dark 
pigment found in the substantia nigra, has been found to chelate and trap metals like iron. The 
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higher levels of iron in the substantia nigra in PD could saturate the chelating sites on 
neuromelanin and lead to an increase of toxic free irons.15 Neuromelanin with iron overload 
has been found both intra- and extra-neuronally in the substantia nigra of patients with PD.16 
Iron in Fe3+ form has also been shown to bind to alpha-synuclein and accelerate its 
aggregation.15,17 Evidence seems to point to that it might not be part of the initiation of the 
disease in PD, but that it could contribute to the progression of the neurodegeneration.15 
1.1.4 Clinical manifestations 
The loss of dopaminergic neurons in the substantia nigra leads to an imbalance in the basal 
ganglia circuitry, which leads to the typical symptoms of PD. A simplified schematic 
representation of the basal ganglia circuitry in health and in PD is shown in Figure 5.  
      
Figure 5: Schematic simplified representation of basal ganglia circuitry in health (left) and in Parkinson’s disease (right). 
Green arrows represent activation and red arrows represent inhibition. 
The typical motor symptoms of PD are bradykinesia, rigidity, resting tremors and postural 
instability.4,5 The onset of the disease is normally unilateral, and this asymmetry typically 
persists also as the disease progresses. As seen in Figure 2, the prevalence of PD increases with 
age, and the average age of onset is in the late fifties.4 What is also typical, is that in addition 
to these motor symptoms, there are so-called non-motor symptoms. These include REM-sleep 
behavior disorder (RBD), olfactory dysfunction, pain, depression and cognitive dysfunction.4,5 
Other common non-motor symptoms are those related to autonomic dysfunction, such as 
orthostatic hypotension and constipation. Som of these non-motor symptoms can often precede 
the onset of motor symptoms by years, and sometimes even decades. 
1.1.5 Diagnosis 
PD is a clinical diagnosis. For the diagnosis of PD, first the criteria for parkinsonism need to 
be fulfilled. Parkinsonism is defined based on three cardinal motor features. Bradykinesia, 
which is an obligate, must be present and combined with either rigidity, resting tremor, or 
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both.18 Bradykinesia is defined as a combination of slow movement and a reduction in 
amplitude or speed as a movement is continued. It is tested by active movements such as finger 
tapping, pronation-supination of the hand or toe tapping. Rigidity is assessed by slowly moving 
the patient’s extremity and is deemed present if a “lead-pipe” resistance is felt, with or without 
a cogwheel phenomenon.18 Resting tremor is a relatively slow tremor 4–6 Hz in a resting 
extremity, and is suppressed when movements are initiated.18 
When parkinsonism has been established as described above, a diagnosis of clinically 
established PD requires the following:18 
• Absence of absolute exclusion criteria 
• At least two supportive criteria 
• No red flags  
Absolute exclusion criteria Supportive criteria Red flags 
Cerebellar abnormalities 
Downward supranuclear gaze palsy 
Diagnosis of behavioral variant 
FTD or primary progressive 
aphasia within 5 years of disease 
Parkinsonian features restricted to 
lower limbs for more than 3 years 
Treatment with dopamine receptor 
blocking or dopamine depleting 
consistent with drug-induced 
parkinsonism 
Absence of levodopa response 
Cortical sensory loss, ideomotor 
apraxia or progressive aphasia 
Normal functional imaging of the 
presynaptic dopaminergic system. 
Alternative condition known to 
cause parkinsonism or other 
diagnosis more likely 
Clear and dramatic response to 
levodopa treatment 
Presence of levodopa induced 
dyskinesias 
Rest tremor of an extremity 
Loss of olfaction, or cardiac 
sympathetic denervation as 
measured by MIBG scintigraphy. 
Rapid progression of gait 
impairment 
No progression of motor symptoms 
over 5 or more years unless related 
to treatment. 
Early bulbar dysfunction. 
Inspiratory respiratory dysfunction. 
Severe autonomic failure in the first 
5 years of disease. 
Recurring falls due to impaired 
balance within 3 years of symptom 
onset. 
Disproportionate anterocollis or 
contractures of hand or feet with 
the first 10 years. 
Absence of non-motor symptoms 
despite 5 years disease duration. 
Unexplained pyramidal tract signs.  
Bilateral symmetric parkinsonism. 
Table 1. Absolute exclusion criteria, supportive critera and red flags, for the diagnosis of Parkinson’s disease. From 
Postuma et al.18 
If an individual does not meet the above criteria for clinically established PD, a diagnosis of 
clinically probable PD could still be possible. Clinically probable PD entails the following;18 
• Absence of absolute exclusion criteria 
• Red flags balanced by supportive criteria – one supportive criteria balances out one red 
flag, with a maximum of two red flags present to fulfil the criteria for probable PD.   
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While PD is a clinical diagnosis, neuroimaging such as magnetic resonance imaging or 
computed tomography is commonly performed, to rule out other possible causes of 
parkinsonism. Other ancillary testing such as 123I-ioflupane single-photon emission computed 
tomography (SPECT), 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) and 
cerebrospinal fluid (CSF) tests can also be part of the investigation in parkinsonism and more 
details on these techniques will follow later in this text. 
1.1.6 Treatment 
The treatment of PD is mainly based on dopaminergic medication. These dopaminergic 
therapies can be divided into three main groups; levodopa, dopamine agonists and inhibitors of 
amine metabolism.4,5 
Levodopa 
Levodopa is a prodrug that, as opposed to dopamine, can enter through the blood-brain barrier. 
When inside the central nervous system, it is decarboxylated to dopamine. To minimize 
peripheral decarboxylation, which would cause side-effects, levodopa is administered together 
with a peripheral decarboxylase inhibitor such as benserazide or carbidopa. 
Dopamine agonists 
Dopamine agonists such as pramipexol, rotigotine and ropinirole exert their effect by directly 
activating dopamine receptors. They typically have a longer half-life than levodopa yielding a 
less pulsatile effect. This is believed to be coupled with a possibly reduced risk of motor 
fluctuations compared to levodopa.4 They are also available in different dosage forms such as 
pills, transdermal patches and subcutaneous injections. 
Metabolism inhibitors 
Metabolism inhibitors can be further subdivided into monoamine oxidase (MAO) inhibitors 
and catechol-O-methyl transferase (COMT) inhibitors. The former inhibiting the clearance of 
dopamine by MAO in the synaptic cleft and thus increasing the dopamine concentration. The 
latter exerting its effect by peripheral inhibition of the COMT-dependent metabolism of 
levodopa, and in that way increasing the levels of circulating levodopa.4 There are also variants 
of COMT inhibitors that in addition to this peripheral effect also have a central effect. 
Treatment of non-motor symptoms 
Regarding the non-motor symptoms, there is often a varied response to the dopaminergic 
therapy, and other medication is often needed to alleviate these symptoms.5 For instance, 
depression can require treatment with selective noradrenaline and serotonin reuptake inhibitors, 
cognitive impairment might require acetylcholine esterase inhibitors and adrenergic agents can 
be used to treat orthostatic hypotension. In the case of hallucinations or other psychotic 
symptoms, the use of atypical neuroleptics can be warranted. 
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Advanced treatments 
There are three commonly used forms of advanced treatments. These are considered when 
severe motor fluctuations cannot be sufficiently handled with the above-mentioned forms of 
medication. Levodopa gel can be continuously administered via a percutaneous endoscopic 
gastro-jejunostomy, and thus bypassing the ventricle giving a much more stable level of 
levodopa in the blood. Apomorphine can be administered subcutaneously via a pump, also 
giving a more even dopaminergic activation. Finally, using deep brain stimulation (DBS), one 
can via intracerebral electrodes stimulate certain basal ganglia regions to achieve a lesion-like 
effect without damaging the actual tissue.4 The two most common targets for DBS are the 
subthalamic nucleus and the globus pallidus interna. By this stimulation, the balance in the 
basal ganglia circuitry can be shifted and parkinsonian symptoms such as bradykinesia, rigidity 
and tremors reduced. 
1.1.7 Clinical scales 
One of the most commonly used scales to assess symptoms and disability in PD are the Hoehn 
& Yahr scale.  
Stage Hoehn and Yahr scale19 
1 Unilateral involvement only, usually with minimal or no functional disability 
2 Bilateral or midline involvement, without impairment of balance 
3 Bilateral disease: mild to moderate disability with impaired postural reflexes; physically 
independent 
4 Severely disabling disease; still able to walk or stand unassisted 
5 Confinement to bed or wheelchair unless aided 
Table 2. The Hoehn and Yahr scale for rating of symptoms in Parkinson’s disease.19 
An updated version of the Hoehn and Yahr scale known as the modified Hoehn and Yahr scale 
also exists, with added stages 1.5 and 2.5.20 The former representing “unilateral and axial 
involvement” and the latter “mild bilateral disease with recovery on pull test”. 
Another commonly used scale is the Unified Parkinson’s Disease Rating Scale, or UPDRS. It 
is based on four sections; 
• Part I: Evaluation of mentation, behavior and mood 
• Part II: Self-evaluationof the activities of daily life (ADL) 
• Part III: Clinician-scored motor evaluation 
• Part IV: Complications of therapy 
This UPDRS scale also exists in a revised edition sponsored by the Movement Disorders 
Society, the MDS-UPDRS.21 
 10 
1.2 PROGRESSIVE SUPRANUCLEAR PALSY 
1.2.1 Background 
Progressive supranuclear palsy (PSP) was described by Steele, Richardson and Olszewski in 
1964, as “a heterogenous degeneration involving the brain stem, basal ganglia and cerebellum 
with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia”.22 They reported 
findings, including histopathology, from 9 patients developing this set of symptoms with the 
central ones being the vertical gaze palsy, axial rigidity and mild dementia. 
1.2.2 Epidemiology 
The prevalence of PSP is around 5-7 per 100 000,23,24 making it a rare disorder, around a 
hundred times less common than PD. There are few known risk factors regarding PSP apart 
from age. Male gender is slightly over-represented in studies with around 55%, but the certainty 
in these numbers are not definite.24 Lesser educational attainment has shown to be associated 
with an increased risk of developing PSP.24 There has also been found an association between 
the H1 haplotype of the tau gene and PSP.25 
1.2.3 Etiology 
PSP is a tauopathy with pathological deposition of tau protein in the 4-repeat isoform in 
aggregates.26 This tau pathology can be found in the frontal and parietal lobes, striatum, 
pallidum, subthalamic nucleus, substantia nigra, red nucleus, pons and cerebellum.27,28 
Pathologically, the picture is relatively typical with these 4-repeat tau inclusions, tufted 
astrocytes and coiled bodies, Figure 6.  
 
Figure 6: Autopsy specimen in progressive supranuclear palsy. Immunostaining for tau displaying a "tufted astrocyte"   
in the center (400x magnification). Image by Jensflorian, used under creative commons license 
(https://creativecommons.org/licenses/by-sa/3.0/), no changes made. 
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1.2.4 Clinical manifestations 
The typical clinical manifestations in classical PSP, is the presence of vertical supranuclear 
gaze palsy, axial rigidity and early falls.24 Mild to moderate cognitive impairment is also 
common, often with irritability or executive dysfunction.27 While this picture is typical after a 
few years of disease, the initial symptoms are usually far more diverse and subtle, including 
gait disturbances, non-specific ocular issues and slowing of saccades.27 The disease is severe 
and relatively rapidly progressive, with life expectancies of 5 to 8 years being reported.27,29 
Several subtypes have been described, with the classical variant being referred to as the 
Richardson-Steele (RS) phenotype. If more Parkinson-like features are present, such as more 
developed rigidity in the extremities, less ocular abnormalities, positive levodopa response or 
resting tremor, they are typically referred to as PSP-parkinsonism (PSP-P).  These patients have 
been shown to have a less severe tau pathology compared to those with PSP-RS.27 Other 
described variants are the PSP-corticobasal syndrome (PSP-CBS), PSP-pure akinesia with gait 
freezing (PSP-PAGF) and PSP-progressive non-fluent aphasia (PSP-PNFA).27 In PSP-CBS, 
the picture is that of an asymmetric disease with prominent dystonia and cortical sensory loss. 
In PSP-PAGF, the central symptoms are gait disturbance and later on also a freezing of gait, 
and in PSP-PNFA a progressive non-fluent, expressive aphasia is present. 
1.2.5 Diagnosis 
The diagnosis of PSP is clinical, and a set of diagnostic criteria commonly used are those 
developed at the NINDS-SPSP international workshop.30 These criteria divide the diagnostic 
certainty into three categories; possible, probable and definite: 
PSP Mandatory inclusion criteria (Litvan et al)30 
Possible • Gradually progressive disorder 
• Onset at age 40 or later 
• Either vertical (upward or downward gaze) supranuclear palsy or both slowing 
of vertical saccades and prominent postural instability with falls in the first year 
of disease onset 
• No evidence of other diseases that could explain the foregoing features 
Probable • Gradually progressive disorder 
• Onset at age 40 or later 
• Vertical (upward or downward gaze) supranuclear palsy and prominent postural 
instability with falls in the first year of disease onset 
• No evidence of other diseases that could explain the foregoing features 
Definite • Clinically probable or possible PSP and histopathologic evidence of typical PSP 
 Table 3. Mandatory inclusion criteria in the diagnosis of PSP. From Litvan et al.30 
To fulfil these criteria, all of the following exclusion criteria must also be absent: 
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Mandatory exclusion criteria (Litvan et al)30 
• Recent history of encephalitis 
• Alien limb syndrome, cortical sensory deficits, focal frontal or temporoparietal atrophy 
• Hallucinations or delusions unrelated to dopaminergic therapy 
• Cortical dementia of Alzheimer's type (severe amnesia and aphasia or agnosia, according to 
NINCDS-ADRA criteria) 
• Prominent, early cerebellar symptoms or prominent, early unexplained dysautonomia (marked 
hypotension and urinary disturbances) 
• Severe, asymmetric parkinsonian signs (i.e., bradykinesia) 
• Neuroradiologic evidence of relevant structural abnormality (i.e. basal ganglia or brainstem infarcts, 
lobar atrophy) 
• Whipple's disease, confirmed by polymerase chain reaction, if indicated 
Table 4. Mandatory exclusion criteria in the diagnosis of PSP. From Litvan et al.30 
Several supportive criteria are also listed, such as symmetric akinesia or rigidity, retrocollis and 
poor levodopa response. These are meant to be more of a guiding nature and not implemented 
in a rule-based way in the diagnostic criteria. 
It has been found that these criteria, while having excellent specificity, might suffer from lower 
sensitivity in early disease and in other variants than PSP-RS.31 This is due to the focus on 
ocular abnormalities, which are not always discernible until later stages. For this reason, among 
others, the MDS criteria for PSP were developed.31 In these criteria, more variants of PSP are 
considered, and there is an additional level of certainty, “suggestive”, which is weaker than 
“possible”. 
Additional testing and procedures are also commonly part of the investigation of suspected 
PSP, such as MRI, CSF examination and FDG-PET. MRI can show different signs consistent 
with PSP such as midbrain atrophy,32 CSF examination can exhibit elevated neurofilament 
light chain protein (NFL)33 and FDG-PET can help differentiate between atypical parkinsonian 
disorders.34 
1.2.6 Treatment 
Levodopa may have some effect on the rigidity and bradykinesia in PSP,24 and is usually tried 
initially. In a cohort consisting of 103 pathologically proven PSP patients, 32% were reported 
to have had some response to levodopa.35 Amantadine may provide some effect on gait and 
apathy.24 Botolinum toxin can be used to ameliorate blefarospasm and apraxia of eyelid 
opening.36,37 
1.2.7 Clinical scales 
A clinical rating scale for assessing symptoms in PSP is the PSP rating scale, developed by 
Golbe et al.38 It consists of 28 items divided into 6 categories; history/daily activities, 
behavioral symptoms, bulbar symptoms, supranuclear ocular motor symptoms, limb motor 
symptoms and gait/midline symptoms. The Hoehn and Yahr scale is also often used in PSP.19 
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1.3 MULTIPLE SYSTEM ATROPHY 
1.3.1 Background 
The name multiple system atrophy (MSA) was first used in 1969,39 but other names for this 
disorder and its variants that were used even earlier were Shy-Drager syndrome, striato-nigral 
degeneration, olivopontocerebellar atrophy.40,41 The last term was described as early as 1900 
by Dejerine and Thomas.42 They partly represent subtypes of what is today defined within the 
MSA entity. 
1.3.2 Epidemiology 
The prevalence of MSA is not completely known, but studies have placed it at ranges from 3.4 
to 4.9 cases per 100 000 people making it roughly as rare as PSP.43 No differences in prevalence 
has been found between the sexes.43 The parkinsonian subtype of MSA is more common than 
the cerebellar subtype in Europe by 2 to 4 times.43 However, the cerebellar subtype was around 
twice as frequent as the parkinsonian subtype in a Japanese cohort consisting of 230 patients 
with MSA.44 This difference in proportions of the respective subtypes could be due to genetic 
or epigenetic factors.43 No single mutations have been found linked to familial forms.45 
1.3.3 Etiology 
Pathologically, varying degrees of degeneration can be found in the striatum, substantia nigra, 
pons and cerebellum, as well as some degree of cortical atrophy.43,45 Histologically, the 
findings are relatively specific for MSA, with alpha-synuclein inclusions within 
oligodendrocytes, so-called glial cytoplasmic inclusions (GCI).42 Other findings include 
neuronal loss with axonal degeneration, myelin degeneration and microglial activation.45 
Examples of GCI within the cerebrum can be seen in Figure 7. 
 
 
Figure 7: Alpha synuclein immunohistochemistry showing glial cytoplasmic inclusions in MSA. Image by Jensflorian, 
used under creative commons license (https://creativecommons.org/licenses/by-sa/3.0/), no changes made. 
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1.3.4 Clinical manifestations 
The central feature of MSA is the early and prominent autonomic failure.43 This autonomic 
dysfunction typically affects cardiovascular and/or urogenital systems. The cardiovascular 
dysfunction showing as severe orthostatic hypotension, and the urogenital dysfunction taking 
the form of erectile dysfunction and/or incontinence.42 MSA is usually divided into subtypes; 
MSA with parkinsonism (MSA-P) and MSA with cerebellar symptoms (MSA-C). MSA-P 
may, especially in early stages, be hard to distinguish from PD.42 It is typically associated with 
bradykinesia, rigidity and impaired balance. Different forms of tremor can be present, but 
classic Parkinsonian “pill-rolling” tremor is unusual.43 Levodopa response is generally poor, 
but some degree of response can be found in around 40% of the patients with MSA-P.43 In 
MSA-C, the picture is that of cerebellar ataxia and oculomotor abnormalities such as 
nystagmus.43 Antecollis, dystonia, RBD, dysarthria, respiratory disturbances and dysphagia are 
also common symptoms in MSA.42,43,45 
1.3.5 Diagnosis 
The second consensus criteria for the diagnosis of MSA define three levels of diagnostic 
certainty; possible, probable and definite MSA.46 It is defined as a sporadic, progressive, adult 
onset disease with the following criteria for the different degrees of certainty. 
MSA Criteria (Gilman et al)46 
Possible • Parkinsonism (bradykinesia with rigidity, tremor, or postural instability) or 
• A cerebellar syndrome (gait ataxia with cerebellar dysarthria, limb ataxia, or 
cerebellar oculomotor dysfunction) and 
• At least one feature suggesting autonomic dysfunction (otherwise unexplained urinary 
urgency, frequency or incomplete bladder emptying, erectile dysfunction in males, or 
significant orthostatic blood pressure decline that does not meet the level required in 
probable MSA) and 
• At least one of the additional features of possible MSA, see following table 
Probable • Autonomic failure involving urinary incontinence (inability to control the release of 
urine from the bladder, with erectile dysfunction in males) or an orthostatic decrease 
of blood pressure within 3 min of standing by at least 30 mm Hg systolic or 15 mm 
Hg diastolic and 
• Poorly levodopa-responsive parkinsonism (bradykinesia with rigidity, tremor, or 
postural instability) or 
• A cerebellar syndrome (gait ataxia with cerebellar dysarthria, limb ataxia, or 
cerebellar oculomotor dysfunction) 
Definite • Neuropathological findings congruent with MSA-P or MSA-C 
Table 5. Diagnostic criteria for possible, probable and definite MSA. From Gilman et al.46 
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Additional features of possible MSA (Gilman et al)46 
Possible MSA-P or MSA-C 
• Babinski sign with hyperreflexia 
• Stridor 
Possible MSA-P 
• Rapidly progressive parkinsonism 
• Poor response to levodopa 
• Postural instability within 3 y of motor onset 
• Gait ataxia, cerebellar dysarthria, limb ataxia, or cerebellar oculomotor dysfunction 
• Dysphagia within 5 y of motor onset 
• Atrophy on MRI of putamen, middle cerebellar peduncle, pons, or cerebellum 
• Hypometabolism on FDG-PET in putamen, brainstem, or cerebellum 
Possible MSA-C 
• Parkinsonism (bradykinesia and rigidity) 
• Atrophy on MRI of putamen, middle cerebellar peduncle, or pons 
• Hypometabolism on FDG-PET in putamen 
• Presynaptic nigrostriatal dopaminergic denervation on SPECT or PET 
Table 6. Additional features for the diagnosis of possible MSA. From Gilman et al.46 
These consensus criteria also list additional features supporting and not supporting a diagnosis 
of MSA, but these features are not included in a rule-based manner. 
The investigation of suspected MSA commonly contains other testing such as CSF analysis, 
autonomic testing, MRI and FDG-PET.47 CSF testing can show elevated levels of NFL33 and 
autonomic testing can assess orthostatic hypotension as well as thermoregulatory 
dysfunction.47 MRI may show signs consistent with MSA such as putaminal atrophy, 
pontocerebellar atrophy and hot cross bun sign.48 FDG-PET can also show patterns of 
metabolism typical for MSA.34 
1.3.6 Treatment 
In MSA-P, initial levodopa response has been reported for a majority of the patients, although 
this response typically declines after a few years as the disease progresses.42,45 Dopamine 
agonists, although probably not as effective as levodopa, can be tried in case of levodopa-
induced dyskinesia.43 Amantadine can potentially have some positive effect, and botulinum 
toxin treatments can be helpful for dystonia.43 In case of orthostatic hypotension, treatment 
with anti-hypotensive medication such as adrenergic or mineral corticoid substances can be 
indicated.42,43 
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1.3.7 Clinical scales 
A dedicated clinical scale for MSA is the Unified MSA Rating Scale (UMSARS), by Wenning 
et al.49 It consists of 4 parts.  
• Part I: Historical review 
• Part II: Motor examination scale 
• Part III: Autonomic examination 
• Part IV: Global disability scale 
As in PSP, the Hoehn and Yahr scale is also often used in MSA.19 
1.4 OTHER TYPES OF ATYPICAL PARKINSONISM 
Corticobasal degeneration (CBD) and dementia with lewy bodies (DLB) are two other 
disorders with parkinsonian symptoms often being part of the clinical picture.  
1.4.1 Corticobasal degeneration 
CBD is a 4-repeat tauopathy with astrocytic plaques and ballooned neurons typically found 
histologically. There is commonly an asymmetric cortical atrophy congruent with the 
asymmetric symptomatology in this disease. Clinically, the picture is of asymmetric rigidity, 
dystonia as well as cortical symptoms such as ideomotor apraxia and aphasia. No effective 
treatments are available, but levodopa or amantadine can be tried and evaluated. For the 
dystonia commonly associated with CBD, botulinum toxin or clonazepam can be helpful. The 
investigation is closely resembling that of PSP and MSA, with MRI, CSF analysis and FDG-
PET commonly being performed. MRI can reveal an asymmetric cortical atrophy. An elevation 
of NFL in CSF is a common finding in CBD, and FDG-PET can often show an asymmetric 
cortical metabolism. 
1.4.2 Dementia with lewy bodies 
DLB is an alpha-synucleinopathy, and Lewy bodies are commonly seen in widespread cortical 
regions. Symptom-wise, a dementia, often with dysexecutive features, visuospatial dysfunction 
and variations in activity and wakefulness is typical. Patient also have fluctuating visual 
hallucinations. Some degree of parkinsonism, such as rigidity and bradykinesia, shall also be 
present. Also typical for DLB is sensitivity to certain medications, where dopaminergic drugs 
such as levodopa often can cause hallucinations and neuroleptics can cause severe rigidity and 
general worsening. To differentiate it from PD, the definition is that if the cognitive symptoms 
appear less than a year after the initial motor symptoms, it meets the criteria for DLB and not 
PD. The clinical investigation often includes MRI, CSF analysis, 123I-ioflupane single-photon 
emission computed tomography as well as extensive neuropsychological testing. Memory 
deficits can be treated with choline esterase inhibitors, and for parkinsonian symptoms, low 
dosages of dopaminergic therapy may have a positive effect. 
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1.5 MAGNETIC RESONANCE IMAGING IN PARKINSONIAN DISORDERS 
1.5.1 Conventional MRI sequences 
Conventional MRI using standard sequences such as T1-weighted imaging, T2-weighted 
imaging including fluid-attenuated inversion recovery (FLAIR), is common in the clinical 
investigation of a patient presenting with parkinsonian symptoms, especially if there is possible 
uncertainty regarding symptomatology. Concerning primarily suspected idiopathic PD, MRI is 
used for the exclusion of alternative diagnoses.50–52 Such alternative diagnoses with different 
typical MRI findings, possibly presenting with parkinsonism, include cerebrovascular disease, 
normal pressure hydrocephalus, brain tumor, multiple sclerosis, PSP, MSA and CBD. These 
disorders can sometimes present, in ways at least initially inseparable from idiopathic PD, with 
symptoms such as rigidity, tremor, bradykinesia or postural instability.4,5,53 It is also important 
to exclude these alternative diagnoses since they may need different medical or surgical 
management. When suspecting atypical parkinsonian syndromes such as PSP, MSA or CBD, 
conventional MRI can in some cases aid clinicians in the diagnostic process.50 
In PSP, mesencephalic atrophy is common. This is the basis for different radiological signs and 
measurements that have been proposed to assess these changes. Typical radiological signs of 
midbrain atrophy observed in PSP are the “hummingbird sign”, the “mickey mouse sign” and 
the “morning glory sign”.32,50 The “hummingbird sign” referring to the appearance of the 
atrophic midbrain on sagittal slices, and the “mickey mouse sign” and “morning glory sign” 
describing the abnormal appearance on axial slices. Examples of these signs are shown in 
Figure 8A-B. For “hummingbird sign” and “morning glory sign” respective sensitivities of 
68% and 50% have been reported, while the “mickey mouse sign” seems to be less prevalent 
and perhaps also less studied.54  
 
Figure 8: MRI in PSP. Hummingbird sign (A). Mickey mouse sign / Morning glory sign (B). Midbrain-to-pons area 
ratio (C). Width of the middle cerebellar peduncle (D). Width of the superior cerebellar peduncle (E). 
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Commonly used measurements in PSP are the midbrain-to-pons ratio (MP-ratio) and the 
magnetic resonance parkinsonism index (MRPI), both showing excellent diagnostic 
discrimination between PSP and other types of parkinsonism as well as from controls. A wide 
range of sensitivities and specificities have been reported for both MP-ratio and MRPI: 64-
100% sensitivity and 80-100% specificity for MP-ratio, and 69-100% sensitivity and 64-100% 
specificity for MRPI.55 The MP-ratio is calculated by measuring the respective midline areas 
on a sagittal slice, illustrated in Figure 8C. For the MRPI, this ratio is inverted and multiplied 
by the width of the middle cerebellar peduncle divided by the width of the superior cerebellar 
peduncle on sagittal and coronal slices respectively, as illustrated in Figure 8C-E. While 
manual measurements such as the MRPI or MP-ratio inherently have the possibility for inter- 
and intra-rater disagreements, an Italian group has recently described a tool for automatic 
calculation of these measurements showing similar results as with manual calculations.56 A 
newer version of MRPI called MRPI 2.0 has recently been proposed, taking into account also 
the width of the third ventricle and the width of the frontal horns. It has been shown to be better 
at separating PSP-P from PD in early stages of disease.57 
In MSA, there are also a number of classical radiological signs reported to indicate disease. 
The most frequent ones are the “hot cross bun sign”, the T2-hyperintensity in the middle 
cerebellar peduncles (“MCP sign”) and putaminal hypointensity on T2-weighted images as well 
as a hyperintense ring around the putamen.42,58 One study reports prevalence of hot cross bun 
sign and MCP sign in MSA at 58% and 50% respectively. Using a gradient recall echo (GRE) 
MRI sequence to assess putaminal hypointensity yielded a sensitivity of 73%. Examples of 
“hot cross bun sign”, “MCP sign” and dorsolateral putaminal hypointensity are shown in 
Figure 9. 
 
 
Figure 9: Signs of MSA. Hot cross bun sign with hyperintensity on T2-weighted image (A). Middle cerebellar peduncle 
hyperintensity (MCP sign) on T2-weighted FLAIR image (B). Hypointensity of the putamen on a gradient recall echo 
(GRE) sequence (C). 
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1.5.2 Advanced MRI sequences 
Susceptibility-related imaging 
Susceptibility weighted imaging (SWI) is an imaging technique in which a GRE sequence is 
used to gather magnitude and phase images which are combined to give the final SWI volume, 
which is sensitive to venous blood, hemorrhage, calcifications and iron deposition.59,60 In the 
SWI-processing, the phase is subjected to a variant of high-pass filtering in which the first step 
is a multiplication of the original complex image with a low-pass Hanning filter.61 The original 
complex image is subsequently divided by the low-passed complex volume to yield a high-
passed filtered phase. The high-pass filtered phase image is converted into a phase mask, where 
negative phase values are linearly distributed 0 to 1, and all positive phase values are set to 1. 
This mask is raised to the power of four and multiplied with the magnitude image to produce 
the final susceptibility weighted image. 
It has been known for a long time that there is abnormal iron deposition in deep nuclei in 
parkinsonism,62 which has been suggested to be due to disease-related disruption of the iron 
homeostasis.63 Since SWI is sensitive to iron deposition, the presence of pathological brain iron 
accumulation can be assessed with SWI and one way of evaluating these changes in PD is the 
so-called “swallow tail sign”.64 It describes the normal hyperintense appearance of nigrosome-
1 within the dorsolateral substantia nigra on SWI. This hyperintensity is commonly lost in 
parkinsonism.65 A study on PD, MSA and PSP showed correct classification against healthy 
controls using this biomarker in 93.2% of the cases.66 Another study on PD, MSA and PSP 
showed similar results with sensitivity and specificity against healthy controls of 88.8% and 
83.6% respectively.67 The presence and absence of the swallow tail sign is shown in Figure 
10A-B. 
A newly developed technique also utilizing phase contrast to assess susceptibility is 
quantitative susceptibility mapping (QSM). QSM takes susceptibility imaging a step further 
and attempts to mathematically deconvolute tissue phase to underlying susceptibility,68,69 
which is a complex inverse and ill-posed problem due to the presence of zeroes along the magic 
angle of the dipole kernel. This problematic double cone is visualized in Figure 10C. Before 
the final deconvolution, the phase must be unwrapped and background fields have to be 
removed. Many techniques have been developed for background field removal including 
SHARP70, V-SHARP71 and projection unto dipole fields (PDF)72. After the tissue phase has 
been acquired, the susceptibility map is calculated using deconvolution with a dipole kernel. 
Commonly used methods include Iterative least-squares (iLSQR)73 and Morphology enabled 
dipole inversion (MEDI)74. A recently described variant of the latter named MEDI+0 includes 
automatic referencing to CSF, enforcing of susceptibility homogeneity within CSF and 
suppression of artifacts near the lateral ventricles in the resulting susceptibility maps.75 
Examples of phase image, tissue phase and quantitative susceptibility map are shown in Figure 
10D-F. Quantitative susceptibility maps have been shown to have a high degree of correlation 
to iron concentrations in brain tissue.76–78 
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Figure 10: Presence of swallow tail sign in a healthy individual (A). Absence of swallow tail sign in a patient with MSA 
(B). Visualization of zeroes in the dipole kernel on the surface of a three-dimensional double cone (C). Illustration of 
QSM processing in a healthy individual, with wrapped phase image (D), tissure phase after phase unwrapping and 
background field removal (E) and the resulting quantitative susceptibility map after deconvolution (F). 
 
QSM techniques have been used in PD to investigate abnormal brain iron accumulation. One 
study reports increased susceptibility levels in the substantia nigra, red nucleus, thalamus and 
globus pallidus in PD compared to healthy controls.79 Another study on QSM in PD vs. controls 
showed only significant increased susceptibility in the substantia nigra, but could from this 
region produce a good diagnostic separation with sensitivity 90% and specificity 86%.80 In 
contrast, another study also using QSM in the substantia nigra to separate PD from healthy 
controls achieved lower diagnostic performance with sensitivities and specificities of around 
70-75%.81 Both these studies, however, show concordance in that QSM seems to be superior 
to R2* in diagnostic performance. Other potential uses of QSM in PD is for structural 
visualization before surgical procedures. QSM has been shown to give higher contrast-to-noise 
ratio and higher inter-rater agreement in the delineation of the subthalamic nuclei (STN) 
compared to T2*.82 QSM also seems to provide contrast useful in identifying the internal globus 
pallidus (GPi) in both PD and controls.83 
QSM has also been used in studies including atypical parkinsonian syndromes. One study used 
a combination of diffusion kurtosis imaging (DKI) and QSM of the lentiform nuclei, and could 
show sensitivities of 83-100% and specificities of 81-100% for diagnostic classification.84 In 
the first QSM study investigating brainstem abnormalities in PSP and MSA, our group could 
show AUCs of 0.97 and 0.98 in separating PSP from PD and healthy controls respectively. 
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Sensitivities and specificities were around 90% or higher in both comparisons.85 In CBD, a 
cortical pattern with layers of different susceptibility can be found.86 
Diffusion weighted imaging 
With specific diffusion weighted MRI sequences, it is possible to image the diffusion of protons 
in vivo in human tissue. One typical way of using this technique to quantify diffusion properties 
is to construct diffusion tensors by acquiring diffusion weighted images in a minimum of six 
directions. This is called diffusion tensor imaging (DTI).87 The diffusion tensor mathematically 
describes the direction and amount of diffusion along three vectors. These values can be further 
evaluated by calculating different diffusion properties, such as mean diffusivity (MD), axial 
diffusivity (diffusion along the mean diffusion direction), and radial diffusivity (diffusion 
perpendicular to the main diffusion direction).88 A commonly used measurement of 
microstructural integrity is the composite diffusion metric called fractional anisotropy (FA).89 
A meta-analysis on DTI studies including 1087 patients with PD and 768 healthy controls 
showed significant differences in FA and MD between the groups in the substantia nigra, the 
corpus callosum, temporal cortex and cingulate cortex.90 A DTI study performed at Karolinska 
University Hospital found reduced FA for substantia nigra in PD patients.91 Another study on 
66 PD patients and 65 healthy volunteers also describes changes in the parietal, occipital, 
insular and cerebellar white matter in PD.92 A study using neuromelanin-based ROIs to assess 
FA in the substantia nigra found lower FA in PD compared to healthy controls.93 In the same 
study, significant differences could not be found using ROIs in the substantia nigra based on 
T2-weighted images. A longitudinal DTI study did not find any difference between PD and 
healthy controls at baseline, but showed a change in nigral FA-levels at the 1.5-2-year follow-
up.94 Callosal FA-values have been shown to yield diagnostic discrimination between PD and 
MSA patients without “hot cross bun sign”, with sensitivity 88% and specificity 83%, albeit 
examined in a small group of eight MSA patients.95 A large meta-analysis also supports the 
findings of diffusional differences between PD and MSA, and showed that putaminal FA-
values could separate MSA-P from PD with an overall sensitivity of 90% and overall 
specificity of 93%.96 Other studies have shown extensive white matter involvement in 
MSA.97,98 Visualizations of an FA-map and MD are shown in Figure 11A-B. 
Tensor based imaging including FA does, however, have certain limitations.99,100 For instance, 
in regions with crossing fibers and thus similar magnitudes of diffusion in all direction, such 
as in the centrum semiovale and deep grey matter structures, the FA-value will be close to 0.101 
Different techniques have been developed to give more detailed microstructural information, 
such as DKI and neurite orientation dispersion and density imaging (NODDI). These methods 
use multiple diffusion weightings in many directions to be able to assess non-Gaussian water 
diffusion.102,103 A study using both DKI and NODDI showed changes in PD in different grey 
matter areas including the striatum and many cortical regions.104 Using DKI, microstructural 
changes have also been shown in PSP and MSA in the midbrain tegmentum and pontine 
crossing tract.105 A study using NODDI in 58 patients with PD and 36 healthy controls showed 
loss of intracellular volume in the substantia nigra and putamen in PD compared to controls. In 
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this study, a diagnostic separation between PD and controls was achieved with a sensitivity of 
88% and a specificity of 83% using intracellular volume values from the substantia nigra pars 
compacta contralateral to the side of the more severe symptoms.106 Examples of NODDI 
volumes showing intraneurite volume fractions and orientation dispersion index are shown in 
Figure 11C-D. It can be mentioned that for NODDI, the intracellular volume fraction and the 
orientation dispersion index are thought to together account for different microstructural 
properties that together can give rise to the same FA.103 
 
Figure 11: Diffusion imaging in a healthy control. Mean diffusivity (A). Fractional anisotropy (B). Map of intraneurite 
volume fraction in a healthy control calculated using the NODDI algorithm with diffusion data gathered in 32 directions 
with b=1000 and 64 directions with b=3000 (C). Orientation dispersion index from NODDI (D). 
 
Functional magnetic resonance imaging 
Functional magnetic resonance imaging (fMRI) employs different techniques to indirectly 
measure brain activity, with the most commonly used method being blood-oxygen level 
dependant (BOLD) contrast imaging.107 Here, changes in blood oxygenation leads to signal 
differences that can be interpreted as changes in brain activity based on neurovascular coupling.  
Studies have shown connectivity impairments in the striatum in PD patients in “off” state.108 
This reduced striatal interconnectivity was associated with decoupling of the striatum from the 
sensorimotor and thalamic networks. Increased striatocortical and thalamocortical connections 
but reduced striatothalamic connectivity is seen in PD when on dopaminergic therapy.109 Intake 
of dopaminergic medication significantly improved striatal connectivity. A study on 51 patients 
with PD and 50 healthy controls showed a diagnostic separation with 92% sensitivity and 87% 
specificity using resting-state fMRI (rs-fMRI) to measure the amplitude of low-frequency 
fluctuations (ALFF) and employing SVM techniques for classification.110 A large meta-
analysis on rs-fMRI studies found evidence of functional impairment in the parietal lobes in 
PD compared to healthy controls.111  
In PSP and CBD, increased functional connectivity was found within networks compared to 
controls, with a larger number of resting state networks affected in CBD.112 Compared to 
healthy volunteers both patient groups exhibited reduced functional connectivity between the 
lateral visual and auditory networks. In PSP, lower functional connectivity was seen between 
the cerebellar and insular networks. Another study showed decreased connectivity in the 
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prefrontal cortex in PSP compared to healthy controls.113 This study also found a correlation 
between lower functional midbrain connectivity and vertical gaze impairment. In MSA, 
changes in ALFF have been seen in different regions of visual cortex and in the right 
cerebellum compared to PD.114 These changes are consistent with known pathological 
involvement in the respective parkinsonian disorder.5,27,42 
 
Magnetization transfer and chemical exchange saturation transfer 
Magnetization transfer (MT) is an imaging technique based on the fact that hydrogen atoms 
not only exist in free water but also in other more complex forms, for example bound to 
macromolecules such as myelin.115 During MRI, the protons bound to macromolecules lose 
their magnetization rapidly and are thus challenging to image. It is, however, possible to image 
them indirectly by MT.116 The MT technique is based on using a preparation pulse aimed to 
resonate with and saturate the protons bound to macromolecules. The bound protons will 
interact and transfer some of their magnetization to the free protons from which signal can be 
obtained (SMT). By repeating the procedure without a saturation pulse (S0), it is possible to 
determine the ratio of which magnetization has been transferred, referred to as the 
magnetization transfer ratio (MTR): 
𝑀𝑇𝑅 =	𝑆! − 𝑆"#𝑆!  
A study on PD, PSP, MSA and healthy controls using MTR found significantly lower levels in 
the globus pallidus in PSP compared to all other groups and in the putamen in MSA compared 
to PD and controls. They also found decreased levels in the substantia nigra in all parkinsonian 
disorders compared to controls.117 A study on PD showed MTR reduction in the substantia 
nigra, the striatum, thalamus and in white matter.118 Two MTR studies on MSA showed 
significantly lower MTR in the pyramidal tracts compared to healthy controls.119,120 A study 
using quantitative MT (qMT), an extension of ordinary MT allowing calculation of additional 
magnetization transfer-related properties, showed significant differences in the substantia nigra 
pars compacta in PD compared to healthy controls.121 
Another imaging technique related to MT is chemical exchange saturation transfer (CEST), in 
which saturation pulses are used to achieve a contrast based on chemical exchange. It allows 
imaging of a multitude of contrasts, including pH imaging, imaging of peptides, metal ion 
detection, temperature imaging, imaging of polyamines and nucleic acids, among others.122 
Two CEST studies using amide proton transfer protocols found significantly lower signals in 
the substantia nigra in PD compared to healthy controls.123,124 Another study using CEST and 
DTI in PD found that while both CEST and DTI found significant changes in the substantia 
nigra PD compared to controls, only CEST could visualize changes also in the putamen and 
the caudate nucleus.125 
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Neuromelanin-sensitive imaging 
Techniques have been developed to visualize melanin using T1-weighted fast spin-echo (FSE) 
sequences.126,127 It is known that neurons in the substantia nigra contain a melanin pigment 
known as neuromelanin. The signal intensity in the above mentioned FSE-sequence has been 
shown to be reduced in the substantia nigra in PD, reflecting degeneration of neuromelanin-
containing neurons. The contrast mechanism for this is thought to be a T1 reduction caused by 
melanin-iron complexes.128 Using neuromelanin-sensitive imaging and a fully automated 
segmentation technique of the substantia nigra and locus coeruleus, excellent discrimination 
between PD and healthy controls have been reported with a sensitivity of 91-92% and a 
specificity of 89%.129 A study exploring neuromelanin-sensitive imaging in atypical 
parkinsonian syndromes has shown reduced nigral volumes with neuromelanin-positivity 
compared to controls in PD, PSP, MSA and CBD.130 In this study, no significant differences 
were seen between the atypical parkinsonian disorders and PD. 
 
Magnetic resonance spectroscopy (MRS) 
Magnetic resonance spectroscopy (MRS) can be used to measure different metabolites in living 
tissue, such as N-acetylaspartate (NAA), creatine (Cr), choline (Cho), glutamate (Glu), 
glutamine (Gln), myo-inositol (mI) and gamma-amino butyric acid (GABA).131,132 From the 
magnetic resonance spectrums, calculations are made to assess either ratios between these 
metabolites or direct quantifications of single metabolites. An MRS study on PD, PSP and 
MSA found reduced NAA/Cho and NAA/Cr ratios in the putamen and pallidum in PSP and 
MSA, suggesting neuronal loss.133 Another study by the same group found reduced NAA/Cho 
ratio in the lentiform nucleus in MSA and PSP compared to PD and healthy controls, and 
reduced NAA/Cr in MSA, PSP and PD compared to controls.134 It has also been shown that 
PSP, CBD, MSA and vascular parkinsonism, but not PD, had reduction of NAA/Cr in the 
frontal cortex.135 This study also reports that PSP, CBD, MSA and PD had lower NAA/Cr 
levels in the putamen, and that CBD had an asymmetry in the putamen compared to controls 
and the other patient groups. A study using quantitative MRS to assess absolute quantities of 
metabolites as opposed to ratios, found lower NAA levels in PSP and MSA compared to PD 
and healthy controls. 136 A study exploring MRS of the cerebellum found reduced NAA/Cr 
ratio in PSP compared to PD and controls, and in MSA of cerebellar subtype (MSA-C) 
compared to all other groups.137 A recent study found lower NAA/Cr in the substantia nigra in 
PD than in controls and a negative correlation between these levels and UPDRS score.138 
Another study found decreased GABA levels in the basal ganglia of PD patients compared to 
controls.139 These findings suggest that different metabolic changes are present in 
parkinsonism, and that these vary between the different parkinsonian disorders. While not used 
clinically at present, further development of these techniques could prove useful in the 
diagnostics of parkinsonism.  
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Ultra high-field MRI 
By increasing the field strength in MRI beyond the typically used 1.5 and 3.0 Tesla (T), it is 
possible to achieve higher signal-to-noise ratio and increased T2*-effects. For research 
purposes there have been studies using 7 T, which provides increased spatial/temporal 
resolution and contrast, allowing better depiction of smaller structures such as the substantia 
nigra.140 The importance of these studies are highlighted by the fact that 7 T was approved for 
clinical use for neurological and musculoskeletal application in Europe and the United States 
in 2017. Using 7 T T2*-weighted MRI, it is possible to visualize anatomical alterations of the 
substantia nigra in PD patients.141 A 7 T study on 30 patients with PD, 7 with MSA, 3 with PSP 
and 26 healthy controls using T2*-weighted imaging found bilateral nigral hyperintensity in all 
healthy controls, and loss of the hyperintensity in all patients with PD, all patients with PSP 
and in all but one of the patients with MSA.142 Another group investigated the consistency of 
the nigrosome-1 visibility in 46 healthy controls.143 They found that nigrosome 1 was at least 
unilaterally visible in 93% of the cases. Another study assessing the same question in 13 healthy 
adults found the sign present in 81% of the cases.144 It has been shown that using 7 T imaging, 
a better separation of the subthalamic nucleus from the substantia nigra is possible.145 Using 7 
T imaging and volume analysis of the subthalamic nucleus, a good diagnostic separation 
between PSP and healthy controls (ROC AUC = 0.89) can be achieved.146 Ultra high-field 
imaging may also assist in surgical planning for DBS of the subthalamic nucleus147 and the 
internal globus pallidus.148 A study using 7 T proton MRS describes elevated GABA levels in 
pons and putamen in PD compared to healthy controls.149 This latter finding is contradictory to 
the newer study mentioned above where lower levels of GABA was seen in the putamen using 
3 T MRS.139  
1.6 SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY AND 
POSITRON EMISSION TOMOGRAPHY IN PARKINSONIAN DISORDERS 
There are several nuclear medicine imaging methods used to assess patients with parkinsonian 
symptoms, to aid in the diagnostics. The most commonly used are the SPECT and PET 
methods, where a radiotracer ligand binds to a target of interest and allows imaging of it.  
1.6.1 123I-ioflupane single-photon emission computed tomography 
In the investigation of parkinsonism, 123I-ioflupane single-photon emission computed 
tomography (DaTSCANTM) can often be a useful ancillary tool. By binding of this ligand to 
the dopamine transporter, it is possible to image the presynaptic dopaminergic system.150 It can 
be useful when facing tremors, to differentiate PD from essential tremor.34 An example of such 
imaging is shown in Figure 12. 
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Figure 12: 123I-ioflupane single-photon emission computed tomography in a patient with essential tremor (A), and a 
patient with Parkinson’s disease (B). Image adapted from Nichols et al. (2018)151. Under creative commons license 
(https://creativecommons.org/licenses/by/4.0/).  
It may also be used more broadly to differentiate neurodegenerative from non-degenerative 
causes of parkinsonism.152 However, it does not allow reliable separation on the individual 
level between the different parkinsonian disorders.34 
1.6.2 18F-fluorodeoxyglucose positron emission tomography 
Using FDG-PET, it is possible to image the cerebral glucose metabolism, and reveal regional 
changes.34 An example of an FDG-PET examination is shown in Figure 13. 
 
Figure 13: 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in 56-year old man. Image is public 
domain. 
 
Typical patterns can often be seen in PD, PSP, MSA and CBD.150 In PD, changes with 
increased activity in basal ganglia areas, pons and cerebellum as well as reductions in certain 
cortical areas have been reported.152 In PSP, decreased metabolism in basal ganglia, 
brainstem and frontal cortical areas can be seen.150 In MSA, the typical picture is that of 
reduced metabolism in areas such as the putamen and cerebellum.34,152 CBD typically shows 
a lateralized decrease in metabolism in the basal ganglia and cortical areas contralateral to 
the clinically most affected side.150 Several studies have shown high sensitivity and 
specificity in separating PD from atypical parkinsonism as well as separating between the 
different atypical parkinsonian disorders.34 
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2 AIMS 
The overall aim of this thesis was to evaluate new MRI techniques and their application in 
parkinsonian disorders. This application includes both the diagnostic capabilities as well as the 
potential knowledge they can bring regarding the different underlying disease pathologies. 
The specific research aims for the studies were: 
- To investigate pathological brain iron accumulation between parkinsonian disorders 
(Studies I & II) 
 
- To assess whether different patterns of brain iron accumulation as measured by QSM 
can be used for diagnostic separation between parkinsonian disorders. (Studies I & II) 
 
- To evaluate an automated approach to brainstem segmentation in PD, PSP and MSA. 
(Study III) 
 
- To compare automated brainstem segmentation with manual brainstem metrics in the 
diagnostics of parkinsonism. (Study III) 
 
-  To investigate the newly developed T1/T2-weighted ratio in PD and atypical 
parkinsonian syndromes, and to assess whether underlying pathology causes different 
patterns of signal change allowing diagnostic separation.  (Study IV)
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3 MATERIAL AND METHODS 
3.1 ETHICAL CONSIDERATIONS 
The Regional Ethical Review Board in Stockholm approved Study I, III and IV (registration 
number 2015/1607-31). The Regional Ethical Review Board in Lund approved Study II and 
IV (registration numbers 290/2008, 557/2008 and 2013/202).  
For the retrospective Study I and III, as well as the retrospective cohort in Study IV, informed 
consent was waived in the groups with disease, in accordance with approval from the Regional 
Ethical Review Board in Stockholm. This waiving of consent was based on the retrospective 
nature of these studies, age of data, full anonymization and the fact that a large proportion of 
the participants were deceased at the time of study initiation. For the healthy controls in Study 
I, written informed consent was obtained. For Study II and the prospective cohort in Study IV, 
written informed consent was obtained from all participants. 
3.2 PROCEDURES AND PARTICIPANTS 
This thesis is based on two patient cohorts; the retrospective Karolinska Imaging in Movement 
Disorders (KIMOVE) cohort and the prospective Biomarkers For Identifying 
Neurodegenerative Disorders Early and Reliably (BioFINDER) cohort (www.biofinder.se). 
Retrospective KIMOVE cohort – included in this cohort are patients who received a diagnosis 
of PD, PSP or MSA at the Neurology Clinic, Karolinska University Hospital, Huddinge, 
Sweden, between the years 2001 to 2015, and underwent a routine MRI examination as part of 
the clinical investigation of their disease. Additionally, 14 healthy controls were recruited, 
matched by age and sex. 
Prospective BioFINDER cohort – included in this cohort are patients and controls and recruited 
from the Neurology Clinic, Skåne University Hospital, Sweden, between 2008 and 2016. The 
participants were assessed by a medical doctor with experience in movement disorders, 
including neurological examination and different rating scales.  
Study I included participants from the retrospective KIMOVE cohort who underwent SWI as 
part of their routine clinical investigation for parkinsonian symptoms. A total of 102 
participants were included, with 62 PD, 15 PSP, 11 MSA and 14 healthy controls. 
Study II included participants from the prospective BioFINDER cohort who underwent SWI 
during their research MRI scan. A total of 199 participants were included; 134 PD, 11 PSP, 10 
MSA and 44 healthy controls. 
Study III included participants from the KIMOVE cohort who had undergone 3D high 
resolution T1-weighted imaging. 196 participants were included, with 140 PD, 29 PSP and 27 
MSA. 
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Study IV included patients from both the retrospective KIMOVE cohort and the prospective 
BioFINDER cohort who had undergone both T1-weighted and T2-weighted MRI. From the 
KIMOVE cohort, 184 participants were included; 129 PD, 28 PSP and 27 MSA. From the 
BioFINDER cohort, 185 participants were included; 125 PD, 11 PSP, 8 MSA and 41 healthy 
controls. 
A schematic representation of the research questions in relation to data sources/participants and 
MRI techniques is shown in Figure 14. 
3.3 CLINICAL EVALUATIONS 
The patients from the KIMOVE cohort 
were reviewed by assessing patient charts. 
From these, Hoehn & Yahr grading was 
assessed retrospectively. For patients with 
PSP, the presence of vertical gaze palsy at 
time of MRI investigation was noted. The 
length of clinical follow-up was also 
registered, as well as changed status of the 
presence of vertical gaze palsy in the 
patients with PSP. 
The patients from the BioFINDER cohort were assessed by a medical doctor with experience 
in movement disorders. The study includes follow-up for up to 10 years, with annual visits 
including (but not limited to) UPDRS, Mini-mental state examination (MMSE) and Hoehn & 
Yahr grading. MRI examinations are performed biannually. Blood tests as well as CSF 
examinations were also performed as part of the full BioFINDER study. For Study II and 
Study IV, the visit with first available MRIs of the relevant types described above was used, 
with clinical evaluations of UPDRS part III, MMSE and Hoehn & Yahr staging recorded. 
3.4 BRAIN IMAGING 
Study I. Acquisition parameters for the MRI sequences used on three Siemens MRI scanners, 
between the years 2008 and 2015, for the SWI in Study I are listed in Table 7. 
Siemens 
MRI 
Scanner 
Field 
strength (T) 
Slice 
thickness 
(mm) 
In-plane 
resolution (mm) 
Flip angle (°) Repetition 
time (ms) 
Echo time 
(ms) 
Trio 3 1.6 0.7 x 0.7 15 28 20 
Avanto 1.5 2.0 0.9 x 0.9 20 49 40 
Aera 1.5 1.6 0.9 x 0.9 20 49 40 
Aera 1.5 2.0 0.9 x 0.9 20 49 40 
Table 7. Acquisition parameters for SWI sequences in Study I. 
Stage Hoehn & Yahr scale19 
1 Unilateral involvement only, usually 
with minimal or no functional disability 
2 Bilateral or midline involvement, 
without impairment of balance 
3 Bilateral disease: mild to moderate 
disability with impaired postural 
reflexes; physically independent 
4 Severely disabling disease; still able to 
walk or stand unassisted 
5 Confinement to bed or wheelchair 
unless aided 
Table 2, reiterated. Hoehn and Yahr scale. 
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Study II. For Study II, SWI as well as 3D magnetization-prepared rapid acquisition gradient 
echo (MPRAGE) T1-weighted imaging were acquired using a 3 T Siemens Skyra scanner. The 
parameters are shown in Table 8. 
Sequence Slice thickness 
(mm) 
In-plane 
resolution (mm) 
Flip angle (°) Repetition 
time (ms) 
Echo time 
(ms) 
Inversion 
time (ms) 
SWI 1.5 0.86 x 0.86 15 27 20 N/A 
T1-weighted 
MPRAGE 
1.0 1.0 x 1.0 9 1900 2.54 900 
Table 8. Acquisition parameters for MPRAGE and SWI sequences in Study II. 
Study III. For Study III, MPRAGE T1-weighted images were acquired between 2001 and 2015 
using different acquisition protocol variants, with 1.5 T (Aera, Avanto and Symphony) and 3 
T (Trio) Siemens scanners. For the 1.5 T scanners, the following acquisition parameters were 
used: slice thickness 1.0 mm to 1.6 mm, in-plane resolution 0.4 x 0.4 mm to 1.3 x 1.3 mm, 
repetition time 1110 ms to 2400 ms, echo time 2.41 ms to 4.38 ms, inversion time 790 ms to 
1100 ms, flip angle 8° to 15°. For the 3 T Trio scanner, the following acquisition parameters 
were used: slice thickness 0.9 mm to 1.5 mm, in-plane resolution 0.9 x 0.9 mm to 1.0 x 1.0 
mm, repetition time 1900 ms to 2300 ms, echo time 2.57 ms to 3.42 ms, inversion time 900 
ms, flip angle 9°. More details regarding the different protocol variants can be found in Paper 
III, supplementary table 1. 
Study IV. For Study IV, participants from the KIMOVE and BioFINDER cohorts who had 
undergone MPRAGE T1-weighted imaging as well as T2-weighted imaging were included. The 
acquisition parameters are summarized in Table 9. 
 
Cohort MRI 
Sequence 
Field 
strength 
(T) 
Slice 
thickness 
(mm) 
In-plane 
resolution 
(mm) 
Flip 
angle 
(°) 
Repetition 
time (ms) 
Echo 
time (ms) 
Inversion 
time (ms) 
KIMOVE T1-weighted 
MPRAGE 
1.5 1.0–1.6 0.4 x 0.4 – 
1.3 x 1.3 
8–15 1110– 2400 2.29–4.38 300–1100 
 T1-weighted 
MPRAGE 
3 0.9–1.5 0.9 x 0.9 – 
1.0 x 1.0 
9 1900–2300 2.57–3.39 900 
 T2-weighted 
spin-echo 
1.5 3.0–5.0 0.4 x 0.4 – 
1.0 x 1.0 
150–180 2500–5474 82–122 N/A 
 T2-weighted 
spin-echo 
3 3.0–4.0 0.3 x 0.3 – 
1.0 x 1.0 
120–150 5530–7150 76–111 N/A 
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Cohort MRI 
Sequence 
Field 
strength 
(T) 
Slice 
thickness 
(mm) 
In-plane 
resolution 
(mm) 
Flip 
angle 
(°) 
Repetition 
time (ms) 
Echo 
time 
(ms) 
Inversion 
time (ms) 
BioFINDER T1-weighted 
MPRAGE 
3 1.0 1.0 x 1.0 9 1900 2.54 900 
 T2-weighted 
spin-echo 
3 5.0 0.4 x 0.4 150 6000 99 N/A 
Table 9. Acquisition parameters for T1-weighted MPRAGE and T2-weighted spin-echo sequences for Study IV. For the 
KIMOVE cohort, 4 different Siemens scanners were used; Aera (1.5 T), Avanto (1.5 T), Symphony (1.5 T) and Trio (3 T). 
For the BioFINDER cohort, a Siemens Skyra (3 T) was used. 
3.5 IMAGE PROCESSING 
Study I 
Susceptibility processing: High-pass filtered phase and magnitude images were acquired. Brain 
extraction was performed on the magnitude images using FMRIb Software Library Brain 
Extraction Tool (FSL BET).153 This mask was then further three-dimensionally eroded and 
used together with the high-pass filtered phase in the QSM processing. The high-pass filtered 
phase was unwrapped using a Laplacian phase unwrapping algorithm and variable-kernel 
sophisticated harmonic artifact reduction on phase data (V-SHARP) was applied for 
background phase removal.71 Finally, the improved sparse linear equation and least-squares 
method (iLSQR) was used to create the final susceptibility maps.73 
Manual segmentation: The susceptibility maps were manually segmented by myself, using 
ITK-SNAP software.154 The two most representative and artefact free slices were chosen from 
each region. The putamen, globus pallidus, substantia nigra and the red nucleus were 
segmented, and susceptibility values extracted. The susceptibility values were normalized 
using CSF in the lateral ventricles. The processing stream is illustrated in Figure 15. 
 
Figure 15. Schematic illustration of the processing in Study I. Figure from Sjöström et al. (2017), supplementary material.85 
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Study II 
Susceptibility processing: The susceptibility processing for Study II follows the same pipeline 
as described above for Study I. 
Manual segmentation: The substantia nigra, the red nucleus and the cerebellar dentate nucleus 
were segmented by a neurologist, Yulia Surova. Susceptibility data from these regions were 
extracted. The manual segmentation is visualized in Figure 16B-C. 
Automated segmentation: FSL FIRST was used to automatically segment globus pallidus and 
putamen from the T1-weighted MPRAGE images.155 The magnitude image was then registered 
to the T1-weighted image using FSL FLIRT,156 and this transformation subsequently applied 
to the susceptibility map. These regions of interest were also subjected to minor manual 
adjustments using ITK-SNAP by myself, to ensure goodness of fit. The automated 
segmentation is shown in Figure 16A. 
 
Figure 16. Illustration of automated segmentation using FSL FIRST (A) and manual segmentations (B-C) for Study II. 
Figure from Sjöström et al. (2019).157 
Study III 
Automated segmentation: FreeSurfer was used to automatically segment brainstem 
substructures; the midbrain, superior cerebellar peduncles, pons and medulla oblongata.158,159 
The volumes in all patient groups were subsequently normalized using the slope of the relation 
between the respective structure and the total intracranial volume in the group with PD, since 
this group was the largest and expected to have the least degree of atrophy compared to PSP 
and MSA. 
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Study IV 
T1/T2-weighted ratio: T1/T2-weighted ratio images were created using the MRTool 
toolbox160,161 running in Statistical Parametric Mapping (SPM) software.162 To summarize, the 
histograms of the T1-weighted and T2-weighted images were normalized using a non-linear 
matching to CSF, soft tissues and bone. The images were then registered together and a T1/T2-
weighted ratio was calculated. The ratio images were further normalized using the mean white 
matter ratio levels of the respective participants. 
Automated segmentation: FreeSurfer was used to automatically segment brain structures from 
the T1-weighted MPRAGE images, including tissue types and subcortical structures.  
Registration to Montreal Neurological Institute (MNI) space and atlas-based region 
extraction: T1-weighted volume was non-linearly registered to the MNI152 template using 
Advanced Normalization Tools (ANTs).163,164 This transform was then applied to the T1/T2-
weighted ratio volumes. For data extraction from the subthalamic nucleus, substantia nigra and 
the red nucleus, respective FSL MIST atlas regions in MNI space were used, and further three-
dimensionally eroded to minimize potential partial volume effects with neighboring tissue.  
3.6 RADIOLOGICAL EVALUATIONS 
Study III 
I manually measured planimetric MP-ratio, MRPI and MRPI 2.0 on all subjects. A random 
subset of 25% of the participants were remeasured by myself and also measured by a specialist 
in neuroradiology, Farouk Hashim, to calculate intra-rater and inter-rater reliabilities using 
intraclass correlation coefficients (ICC). The manual measurements are shown in Figure 17. 
 
Figure 17. Manual segmentation of midbrain and pons are (A), middle cerebellar peduncle width (B), width of superior 
cerebellar peduncles (C), width of the third ventricle (D) and the width of the frontal horns (E) 
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3.7 STATISTICAL ANALYSIS 
SPSS 23.0 (IBM, USA) was used for Study I, SPSS 24.0 for Study II, and SPSS 26.0 for Study 
III and Study IV. Normality was assessed using Shapiro-Wilk test for Study I, Study III and 
Study IV. Normality was assessed using Kolmogorov-Smirnov for Study II. Group 
comparisons were performed using one-way ANOVA or independent samples Kruskal-Wallis 
test, and pairwise comparisons were performed using independent samples t-test or Mann-
Whitney u-test. For Study I and Study II, two-way ANCOVA and one-way ANCOVA was 
also used to asses group differences, respectively. In Study I, ordinal logistic regression was 
used to assess effects of increased susceptibility in different regions on the Hoehn & Yahr score 
in patients with PD. For Study II, Pearson partial correlation was used to assess correlations 
between variables. Differences in distribution between groups were tested using Pearson’s χ2 
test. Diagnostic accuracy was investigated using area under receiver operating characteristic 
curves (ROC AUC). Diagnostic performance in Study III was also further assessed using 
McNemar test. Pairwise comparisons in Study I and III were corrected for multiple 
comparisons using the False Discovery Rate procedure as described by Benjamini and 
Hochberg.165 Pairwise comparisons in Study III were corrected for multiple comparison using 
the Bonferroni method. Intra- and inter-rater reliabilities for Study III were calculated using 
intraclass correlation coefficients (ICC), with a two-way mixed model for absolute agreement 
on single measures. Intra- and inter-scanner reliabilities in Study III were also assessed by 
calculating coefficients of variation (CoV). Statistical significance was defined as an a-level 
of 0.05, after correction for multiple comparisons where such was performed. 
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4 RESULTS 
4.1 STUDY I 
Demographics of study participants 
88 patients who had undergone SWI as part of routine clinical investigation as well as 14 age- 
and sex-matched controls were included in this study. The demographics of the participants 
are shown in Table 10. 
 
N Mean age 
(Y) 
Gender 
(F/M) 
Mean symptom 
 Duration (Y) 
Associated features  
at time of MRI 
DAT SPECT 
positive/total 
examined (N/N) 
PD 62 65.2 ± 10.5 19/43 4.7 ± 4.4 Hoehn & Yahr 
Stage 1/2/3/4/5 (N): 
17/24/16/5/0 
46/46 
PSP 15 69.1 ± 6.0 3/12 2.8 ± 1.0 Hoehn & Yahr 
Stage 1/2/3/4/5 (N): 
0/1/7/5/2 
Postural instability (93.3%, n=14) 
Vertical gaze palsy (80.0%, n=12) 
DOPA-responsive (0%, n=0) 
8/8 
MSA 11 68.9 ± 13.1 5/6 3.6 ± 2.7 Hoehn & Yahr 
Stage 1/2/3/4/5 (N): 
0/1/0/8/2 
Orthostatism (36.4%, n=4) 
Incontinence (54.5%, n=6) 
DOPA-responsive (27.3%, n=3) 
3/3 
Controls 14 63.5 ± 5.3 5/9 
 
  
Table 10. Demographics of the participants in Study I. Abbreviations: F = female; M = male, DAT = dopamine 
transporter. 
Reliability and reproducibility 
To investigate reproducibility, one of the healthy controls was examined on all three different 
MRI scanners. No significant differences in susceptibility were found in any of the regions of 
interest between the scanners. Susceptibility differences in all regions between the scanners 
were also investigated within the different groups using one-way ANOVA, and no such 
differences were found. 
Validity of QSM measurements 
Susceptibility values in 8 different regions in the healthy controls in our study were compared 
to known iron concentrations in these regions, as measured by Langkammer et al. in a post-
mortem validation study.76 A strong correlation was found, with r = 0.96, p < 0.001.  
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Group differences 
Differences in susceptibility between the groups are shown in Figure 18. Notably, higher 
susceptibility was seen in the red nucleus and globus pallidus in PSP compared to all other 
groups. Higher susceptibility was also found in the substantia nigra in all patient groups 
compared to healthy controls. 
 
Figure 18. Susceptibility levels in the regions of interest. Significant differences are shown below the plot. Abbreviations: 
CTRL = control; ppm = parts per million. Figure from Sjöström et al. (2017).85 
Diagnostic performance 
The highest degrees of diagnostic separation were found in the red nucleus for separating PSP 
from PD (AUC 0.97), MSA from PD (AUC 0.86), PSP from MSA (AUC 0.75), PSP from 
controls (AUC 0.98) and MSA from controls (AUC 0.86). For separating PD from controls, 
best diagnostic performance was seen in the substantia nigra with AUC 0.71. 
Features associated with odds of having higher Hoehn and Yahr score in the PD group 
Using ordinal logistic regression, features including age, gender, disease duration and 
susceptibility in the globus pallidus, putamen, substantia nigra and the red nucleus were entered 
into a model to investigate associations with odds of having higher Hoehn and Yahr scores. An 
increase in age and disease duration were found to be associated with increased odds of having 
a higher Hoehn and Yahr score (p = 0.012 and p = 0.002 respectively). Increased susceptibility 
in the putamen was associated with increased odds of having a higher Hoehn and Yahr score 
(p = 0.040).  
  39 
4.2 STUDY II 
Demographics of study participants 
For this susceptibility mapping study, 199 participants from the BioFINDER cohort were 
included; 134 PD, 11 PSP, 10 MSA and 44 healthy controls. The demographics of the study 
participants are shown in Table 11. 
Demographic variables PD PSP MSA Controls 
Participants, N 134 11 10 44 
Age at clinical visit, y, mean ± SD 66.9 ± 9.6 72.2 ± 5.5 63.4 ± 11.4 66.0 ± 7.8 
Gender, F/M 48/86 6/5 6/4 26/18 
Disease duration, y, mean ± SD 6.0 ± 5.0 5.5 ± 2.8 4.7 ± 2.2 N/A 
UPDRS-III, score, median (IQR) 13.5 (7-22.25) 36 (28-58) 38.5 (24-52.5) 1 (0-2) 
Hoehn & Yahr, score, median (IQR)  2 (1-2.5) 4 (3-5) 4 (3-5) 0 (0-0) 
MMSE, score, median (IQR) 28 (27-29) 27 (19-28) 29 (26.75-29) 29 (28-30) 
Dementia, N 18 4 0 0 
Table 11. Demographics of participants in Study II. Abbreviations: IQR = interquartile range. 
Group differences 
Susceptibility levels and their distribution between the groups are shown in Figure 19. 
 
Figure 19. Susceptibility levels in the different groups. Red line denotes median and blue lines represent the interquartile 
range. Dagger (†) indicates the use of Mann-Whitney U-test due to non-normality of data. Significant differences are shown 
beneath respective plots. One asterisk (*) represents a p-value of less than the Bonferroni corrected a-level of 0.0017, two 
asterisks (**) represent p < 0.0001. Figure from Sjöström et al. (2019).157 
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There is a marked increase in susceptibility in the red nucleus in PSP compared to all other 
groups (all p-values < 0.0001). There was also an increased susceptibility in globus pallidus in 
PSP compared to PD and controls (both p-values < 0.0001). Susceptibility in the putamen was 
increased in PSP and MSA compared to PD and healthy controls (all p-values < 0.0001). The 
dentate nucleus also exhibited elevated susceptibility in PSP compared to PD and controls (both 
p-values < 0.0001), and in MSA compared to PD (p = 0.0016). 
Diagnostic performance 
ROC curves were used to investigate diagnostic performance in separating the groups using 
susceptibility levels from the different regions. As seen in Figure 20, the highest AUC for 
separating PSP from PD, MSA and controls was found in the red nucleus, with respective 
AUCs 0.98, 0.96 and 0.96. There was also excellent diagnostic separation between PSP and 
PD in the putamen, substantia nigra and the dentate nucleus. For separation between PSP and 
controls, excellent performance was also seen in the substantia nigra (AUC 0.95) and in the 
dentate nucleus (AUC 0.92) 
 
Figure 20. ROC curves depicting the diagnostic separation between PSP and the other groups. Dagger (†) indicates that 
the sensitivities and specificities are for the reverse comparison. Abbreviations: DN = dentate nucleus; GP = globus 
pallidus; PUT = putamen; RN = red nucleus; SN = substantia nigra. Figure from Sjöström et al. (2019).157 
For MSA, good separation from PD and controls was seen using putaminal susceptibility (AUC 
0.82 and AUC 0.80, respectively). Using dentate nucleus susceptibility, good diagnostic 
separation between MSA and PD was also seen (AUC 0.80). By combining all regions of 
interest in a discriminant analysis 97.2% of cases were correctly classified in PSP vs PD. Using 
the same method for separating PSP and MSA, 90.5% of cases were correctly classified.  
Correlations between susceptibility, clinical scores and disease duration in the PD group 
In the PD group, we found a significant correlation between putaminal susceptibility levels and 
UPDRS-III (r = 0.213, p = 0.015). There were also significant correlations between disease 
duration and susceptibility in the globus pallidus (r = 0.198, p = 0.023) and substantia nigra (r 
= 0.251, p = 0.004). 
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4.3 STUDY III 
Demographics of the study participants 
In this retrospective study, 196 participants in the KIMOVE cohort who had undergone T1-
weighted MPRAGE imaging as part of routine clinical investigation were included. The 
demographics of the study participants are shown in Table 12. 
 
N Mean age, 
Y±SD  
Gender 
Female/Male, N 
Mean symptom 
 Duration, Y±SD 
Hoehn & Yahr 
Stage 1/2/3/4/5, N 
MRI field 
strength 
1.5T/3T, N/N 
VSGP at 
time of 
MRI 
PD 140 65.3 ± 9.8 48/92 5.3 ± 5.0 32/64/25/19/0 95/45 - 
PSP 29 69.1 ± 6.7 11/18 3.1 ± 1.8 1/2/13/10/3 23/6 15/29 
MSA 27 68.6 ± 8.5 14/13 2.4 ± 1.5 2/4/3/17/1 20/7 - 
Table 12. Demographics of the participants in Study III. Abbreviations: VSGP = vertical supranuclear gaze palsy. 
Reliability assessments 
Volumetric reliability: To assess intra- and inter-scanner reliabilities, 3 healthy controls were 
examined using 3 of the different MRI scanners, with 2 examinations in each scanner. 
Brainstem substructures were segmented, and intra- and inter-scanner intraclass correlation 
coefficients were calculated. ICC-values showed excellent intra-scanner reliabilities for the 
midbrain (ICC 0.95), pons (ICC 1.00) and medulla oblongata (ICC 0.97). In the superior 
cerebellar peduncles (SCP), a lower intra-scanner ICC was seen at 0.53. Examining inter-
scanner ICC, we found excellent reliability for the midbrain (ICC 0.91), pons (ICC 0.99) and 
medulla oblongata (ICC 0.93). A lower inter-scanner ICC was seen in the SCP (ICC 0.27). 
Planimetric reliability: A randomly selected subset of 25% of the participants were re-
measured by the original rater (Henrik Sjöström, a specialist in neurology) and measured by a 
second rater (Farouk Hashim, a specialist in neuroradiology) for calculation of reliability 
measures. Intra-rater reliability was found to be excellent for the manual scores; MP-ratio (ICC 
0.96), MRPI (ICC 0.92) and MRPI 2.0 (ICC 0.97). Inter-rater ICC between the raters was 
excellent for MP-ratio (ICC 0.94), good for MRPI 1.0 (ICC 0.88) and excellent for MRPI 2.0 
(ICC 0.93). 
Pooling of data: No group differences were found regarding distribution across the four MRI 
scanners (p = 0.167), in field strength (p = 0.424), pixel spacing (p = 0.719) or slice thickness 
(p = 0.705). No differences in brainstem volumes depending on field strength were found in 
any of the groups. The data were hereafter combined for the remaining analyses. 
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Group comparisons of normalized brainstem volumes 
Distribution of the normalized brainstem volumes are visualized in Figure 21. PSP exhibited 
lower volumes compared to PSP and MSA in the midbrain (both p-values < 0.001), SCP (p < 
0.001 and p = 0.028, respectively) and the medulla oblongata (both p-values < 0.001). In PSP 
and MSA, lower pons volumes were seen compared to PD (both p-values < 0.001). 
 
Figure 21. Normalized brainstem volumes in the different groups. One asterisk (*) indicates differences with p < 0.05 
and two asterisks (**) indicated differences with p < 0.001, after correction for multiple comparisons using the False 
Discovery Rate procedure. Dagger (†) indicates the use of Mann-Whitney U-test due to non-normality of data. 
Diagnostic performance 
Midbrain and medulla oblongata volumes were the most successful brainstem volumes in 
separating PSP from PD (AUC 0.90 and 0.85, respectively) and PSP from MSA (AUC 0.80 
for both volumes). Using the midbrain volume to separate PSP from PD, we found a sensitivity 
of 79% and a specificity of 89% at an optimal cut-off defined as the point on the ROC curve 
closest to the upper left corner. For separation between PSP and MSA, the volume with best 
diagnostic performance was also the midbrain, with a sensitivity of 76% and specificity of 78%. 
Composite variables were created, and the product of the midbrain and medulla oblongata 
volumes was excellent at separating PSP from PD (AUC 0.92) and at separating PSP from 
MSA (AUC 0.85). By comparing ROC AUC, we found that the midbrain volume showed 
significantly better diagnostic performance than MP-ratio (p = 0.019), MRPI (p = 0.007) and 
MRPI 2.0 (p = 0.021) in separating PSP from PD. We also found that the product of the 
midbrain and medulla oblongata volumes also had significantly better performance than MP-
ratio (p = 0.005), MRPI (p = 0.003) and MRPI 2.0 (p = 0.007 respectively) in separating PSP 
from PD. The volumetric midbrain-to-pons ratio performed significantly worse than its 
planimetric counterpart. No volumetric variable had significantly better diagnostic 
performance than any of the planimetric variables in separating PSP from MSA. 
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4.4 STUDY IV 
Demographics of study participants 
This study on T1/T2-weighted ratio in parkinsonism included patients from both the 
retrospective KIMOVE cohort and the prospective BioFINDER cohort, who had undergone 
T1-weighted and T2-weighted MRI. 184 participants were included from the KIMOVE cohort, 
and 185 participants were included and from the BioFINDER cohort. Demographics of the 
included study participants are shown in Table 13. 
KIMOVE 
cohort 
N Mean age, 
Y±SD  
Gender 
Female/
Male, N 
Mean symptom 
Duration, Y±SD 
Hoehn & Yahr 
Stage 
1/2/3/4/5,N 
MRI field strength 
1.5T/3T, N/N 
VSGP at 
time of 
MRI, N 
PD 129 65.3 ± 9.6 45/84 5.2 ± 4.9 31/58/23/17/0 89/40 - 
PSP 28 68.8 ± 6.6 11/17 3.1 ± 1.7 1/2/13/9/3 22/6 17 
MSA 27 68.6 ± 8.5 14/13 2.4 ± 1.5 2/4/3/17/1 20/7 - 
BioFINDER 
cohort 
N Median age, 
Y (IQR)  
Gender 
Female/
Male, N 
Mean symptom 
duration, Y±SD 
Hoehn & Yahr 
Stage 
0/1/2/3/4/5,N 
UPDRS-3 Mean 
score±SD 
MMSE 
Mean 
score±SD 
PD 125 68 (11.5) 46/79 6.1 ± 5.1 1/39/60/18/6/1 16.7 ± 11.8 27.2 ± 3.3 
PSP 11 72 (5.0) 6/5 5.5 ± 2.9 0/0/0/6/2/3 35.7 ± 17.3 25.8 ± 4.3 
MSA 8 62 (19.5) 5/3 5.0 ± 2.2 0/0/0/2/3/3 40.9 ± 18.5 27.9 ± 1.7 
Controls 41 68 (12.5) 23/18 - 41/0/0/0/0/0 1.5 ± 2.4 28.6 ± 1.4 
Table 13. Demographics of the participants in Study IV. Abbreviations: IQR = interquartile range; VSGP = vertical 
supranuclear gaze palsy. 
Group comparisons 
KIMOVE cohort 
In the retrospective cohort, we found higher T1/T2-weighted ratio in PSP compared to PD in 
the caudate nucleus (p = 0.015) and putamen (p = 0.001), and lower ratio in the thalamus (p = 
0.015), red nucleus (p = 0.013) and subthalamic nucleus (p = 0.019). We found lower T1/T2-
weighted ratio in PSP compared to MSA in the thalamus (p = 0.017), red nucleus (p = 0.006) 
and subthalamic nucleus (p = 0.012). When comparing MSA to PD, a higher T1/T2-weighted 
ratio was seen in the caudate nucleus (p = 0.028) and putamen (p = 0.011). When comparing 
MSA to PD tendencies of higher pallidal T1/T2-weighted ratio in MSA and lower pontine ratio 
was also seen, with significant pairwise tests but non-significant ANOVA at the group level. 
T1/T2-weighted ratio values in the different regions in the KIMOVE cohort are visualized in 
Figure 22. 
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Figure 22. Mean T1/T2-weighted ratio in the different regions in the retrospective KIMOVE cohort. Error bars show 95% 
confidence intervals of the mean. 
BioFINDER cohort 
Regions displaying significant differences, with the addition of the substantia nigra and 
midbrain, were carried on for analysis in the prospective BioFINDER cohort. Here, we could 
validate the findings of lower T1/T2-weighted ratio in PSP compared to PD, MSA and controls 
in the red nucleus (p = 0.006, p = 0.012 and p = 0.008 respectively) and in the subthalamic 
nucleus (p = 0.013, p = 0.033 and p = 0.047 respectively). We also found lower ratio in the 
midbrain in PSP compared to PD (p = 0.026) and MSA (p = 0.009). There were also tendencies 
of higher T1/T2-weighted ratio in PD and MSA in the substantia nigra compared to controls, 
with significant pairwise tests but non-significant ANOVA in the group level analysis. In the 
same way, PSP showed tendencies of higher ratio in the caudate nucleus compared to controls, 
and MSA showed tendencies of higher pallidal T1/T2-weighted ratio compared to controls. 
T1/T2-weighted ratio values in the different regions in the BioFINDER cohort are shown in 
Figure 23. Significant p-values from the pairwise comparisons are visualized in Figure 24. 
 
Figure 23. Mean T1/T2-weighted ratio in the different regions in the prospective BioFINDER cohort. Error bars show 95% 
confidence intervals of the mean. 
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Figure 24. Visualization of significant group differences in white matter normalized T1/T2-weighted ratio in the 
prospective BioFINDER cohort. Regions with significant difference in pairwise testing are colored according to p-value to 
indicate the level of significance of increased (red – yellow) or decreased (dark blue – light blue) ratio. Note that all p < 
0.05 from pairwise testing are depicted, regardless of results from ANOVA or Kruskal-Wallis test.  
Diagnostic performance 
Diagnostic performance of the T1/T2-weighted ratio was first analyzed in the KIMOVE cohort 
using ROC AUC. The regions showing the best diagnostic performances in differentiating PSP 
from PD were the thalamus (AUC 0.65), caudate nucleus (AUC 0.67), putamen (AUC 0.69), 
red nucleus (AUC 0.65) and the subthalamic nucleus (AUC 0.65). For differentiating MSA 
from PD, the best diagnostic performances were found in the caudate nucleus (AUC 0.64), 
putamen (AUC 0.66), pallidum (AUC 0.63) and pons (AUC 0.63). The regions with best 
diagnostic performances in separating PSP from MSA were the thalamus (AUC 0.69), red 
nucleus (AUC 0.72) and the subthalamic nucleus (AUC 0.72).  
Composite variables based on the regions with significant differences in the KIMOVE cohort 
were then diagnostically evaluated in the BioFINDER cohort. For separating PSP from PD, 
this variable consisted of ratios from the following regions; (Caudate * Putamen) / (Thalamus 
* Red nucleus * Subthalamic nucleus) and yielded an AUC of 0.82. For separating MSA from 
PD, the composite variable consisted of (Caudate * Putamen * Pallidum) / Pons and yielded 
and AUC of 0.59. For separating PSP from MSA, the composite variable consisted of 
(thalamus * red nucleus * subthalamic nucleus) and yielded and AUC of 0.86. 
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5 DISCUSSION 
A common problem in the movement disorder clinic is to differentiate PD from PSP and MSA. 
While being distinct disease entities when considering underlying pathophysiology, they often 
present with similar symptoms of parkinsonism. A correct and early diagnosis is important in 
the choice of medication and involvement of other health specialties such as physiotherapists, 
speech therapists and dieticians.  
The overarching aim of my thesis is to investigate different MRI techniques and evaluate their 
potential as diagnostic biomarkers in parkinsonian disorders, to hopefully contribute to better 
clinical care and to build more knowledge regarding these disorders and techniques together 
with the research community. 
5.1 STUDY I AND II 
The results from Study I show that it is possible to process high-pass filtered phase images 
from clinical SWI examinations into susceptibility maps by using QSM techniques, and that 
these maps can be used to investigate pathological brain iron accumulation in parkinsonian 
disorders. There was a substantial elevation of susceptibility in different regions in PSP and in 
MSA compared to PD. Most notable is the increased susceptibility in the red nucleus and 
globus pallidus in PSP compared to all other groups. These findings are congruent with known 
pathological involvement in these regions.27,150 Another interesting finding in Study I is the 
elevated susceptibility in the putamen in MSA compared to PD and controls. This finding is 
also in line with the picture in MSA with both pre- and post-synaptic dopaminergic 
degeneration and histopathological findings in this region.166 All patient groups exhibited 
elevated susceptibility levels in the substantia nigra compared to healthy controls. Regarding 
diagnostic performance, the results from Study I showed that the red nucleus susceptibility 
stood out as a promising potential biomarker in the separation of PSP from other causes of 
parkinsonism.  
Study II largely corroborates our findings from Study I in a coherent and prospectively 
recruited cohort, with elevated susceptibility in the red nucleus in PSP compared to all other 
groups, and elevated susceptibility in the globus pallidus compared to PD and healthy controls. 
The diagnostic performance of the red nucleus susceptibility in separating PSP from other 
parkinsonian disorders and controls was also corroborated, and it remained the most promising 
biomarker region. Other notable findings in Study II are the elevated putaminal susceptibility 
levels in MSA compared to PD and controls, consistent with the results from Study I. The 
elevated pallidal susceptibility in PSP was replicated in Study II in relation to PD and controls 
but not to MSA. We believe this might, in part, be due to the slightly lower number of PSP and 
MSA patients in the BioFINDER cohort (11 PSP and 10 MSA in BioFINDER, compared to 
15 PSP and 11 MSA in the KIMOVE cohort). 
To our knowledge, we are the first group to demonstrate this highly increased susceptibility in 
the red nucleus in PSP compared to PD (Study I and II), MSA (Study I and II) and controls 
(Study II). Using this region as a diagnostic biomarker to separate PSP from PD, MSA and 
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controls, we find promising accuracies as measured by ROC AUC. Other potential biomarker 
regions are the putamen and the dentate nucleus for separating atypical parkinsonism from PD. 
Regarding associations and correlations between susceptibility measurements and clinical 
scores in PD, results from Study I showed that an increase in putaminal susceptibility was 
associated with an increased risk of having a higher Hoehn and Yahr score. Study II could 
similarly show that that there is a correlation between putaminal susceptibility and UPDRS part 
III. This is interesting considering that the putamen is an area that, together with the substantia 
nigra, has been shown to have increased iron accumulation in PD both in MRI and postmortem 
studies.167 
When viewed in relation to QSM studies in Parkinsonism, such as those by Murakami et al168 
and Barbosa et al,81 they found increased susceptibility in in the substantia nigra in PD 
compared to controls. While we found similar findings in Study I, we could not validate this in 
Study II. We cannot definitively explain this, but one possible reason could be differences in 
the methodology of the manual segmentations. In Study I, the two centermost representative 
slices were segmented in all regions. In Study II, all slices where the respective regions were 
visible and artefact-free were segmented. This difference could lead to an effective decrease, 
in Study II, of the resulting levels in the groups with higher susceptibility since all slices with 
lower susceptibility would also be included until the region was not visible for segmentation. 
5.1.1 Study limitations 
Study I 
Firstly, the retrospective nature of the study means that the assessments of Hoehn and Yahr 
scores and screening for clinical signs such as vertical supranuclear gaze palsy or autonomic 
dysfunction is done through review of the clinical patient charts. The diagnoses have, however, 
been determined by specialists in neurology according to established diagnostic criteria,30,46,169 
and the diagnostic certainty is also strengthened by the fact that the patients were subjected 
long-time follow up at the neurology department. Secondly, the study participants were 
scanned using three different Siemens scanners. No differences were found between the 
susceptibility levels in the different MRI protocols in any of the groups. One of the healthy 
controls was examined using all three scanners, and no differences in susceptibility was found 
in any of the regions of interest between the scanners. The main group analysis was also carried 
out as a two-way ANCOVA where the MRI protocol was one of the factors to further account 
for possible differences. 
Study I and II 
When considering the common methodology for Study I and II, there are some possible 
limitations that apply to both studies. The high-pass filtered nature of the phase images used in 
these studies, which is done as part of the standard clinical SWI processing, can possibly reduce 
the contrast of the phase image. Technically, it is a form of background field removal. 
Background field removal is also part of the standard QSM processing, but more recently 
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developed techniques using projection onto dipole fields72 or laplacian variants71 that combine 
phase unwrapping and background field removal are typically more suited to preserving such 
contrast. The results from our studies prove, however, that useful information regarding 
susceptibility differences are still preserved and can extracted from this type of data. The data 
is also representative of MRI procedures commonly performed in routine clinical practice. 
Another limitation common to both studies, is the somewhat low number of patients with 
atypical parkinsonian syndromes. This, however, is a universal issue shared with most studies 
on PSP and MSA, considering that these are indeed rare disorders. 
5.1.2 Post-publication developments 
After publication, there has been some research activity in the field of QSM in parkinsonian 
disorders. A study by Jin et al. investigated the combination of neuromelanin-sensitive MRI 
and QSM imaging of nigrosome-1, and found that these two biomarkers together can aid in the 
differentiation of PD from essential tremor.170 Shahmaei et al. investigated differences between 
patients with PD and healthy controls, and also correlations to disease stage as measured by 
Hoehn and Yahr.171 Similar to our findings in Study I, they also show increased nigral 
susceptibility in PD, but also report elevated susceptibility in the red nucleus, thalamus and 
globus pallidus compared to healthy controls. They found a significant association with disease 
stage in all nuclei. There are still some differences in the reports of susceptibility levels between 
studies, with the original studies on QSM in PD by Barbosa et al.81 and Murakami et al.168 only 
showed significant increase of susceptibility in the substantia nigra. Langkammer et al., on the 
other hand, found elevations also in the red nucleus, thalamus and globus pallidus in addition 
to the substantia nigra.79 Not only the actual levels of susceptibility but also their texture seem 
to be different between patients with PD and controls. Li et al. report that first- and second-
order texture characteristics from QSM images of the substantia can be used to separate PD 
from controls.172 More specific regional analysis in the substantia nigra has led to deeper 
understanding of where the susceptibility changes are most prominent. Bergsland et al. have 
now shown that iron accumulation in the substantia nigra in PD is located mainly in the ventral 
parts of the structure.173 There has also been additional studies in QSM in atypical 
parkinsonism. Miyata et al. have shown interesting results in separating CBD from PSP by 
assessing CBD-specific susceptibility layers in the cerebral cortex.86  
More closely related to our Studies I and II, two studies assessing the red nucleus as a possible 
biomarker have been published recently. One smaller study by Azuma et al. found, slightly in 
discordance with our results, that the globus pallidus and not the red nucleus seemed to be most 
promising in separating PSP from PD.174 This study, however, only included 8 patients with 
PSP and thus makes the reported ROC AUCs and diagnostic performance less reliable. A larger 
study by Mazzuchi et al. including 15 patients with PSP, report that the susceptibility in the red 
nucleus yielded the highest diagnostic accuracy for PSP,175 which is in concordance with our 
results from Study I and Study II. 
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5.2 STUDY III 
To our knowledge, this is the first study directly comparing automated brainstem volumetry to 
manual planimetric measurements in the differentiation of PSP from other causes of 
parkinsonism. Our results show that there are significantly lower volumes in the midbrain, 
superior cerebellar peduncles and medulla oblongata in PSP compared to PD and MSA. There 
were also reduced pontine volumes in both PSP and MSA compared to PD.  
The results from Study III clearly show that normalized midbrain volume can potentially be 
used as a biomarker to separate PSP from PD, and that a product of the normalized midbrain 
and medulla oblongata volumes could improve the diagnostic separation of PSP from both PD 
and MSA. We did not find any particular brainstem structure where the volume could be used 
to distinguish MSA from PD in any reliable way. The midbrain volume performed better than 
planimetric measurements (MP-ratio, MRPI 1.0 and MRPI 2.0) in separating PSP from PD, 
and on par with planimetry for separation between PSP and MSA. Our findings are in line with 
the results of a recent study by Pyatigorskaya et al.,176 where significant midbrain atrophy with 
loss of volume was found in PSP using automated segmentation techniques. Also, Bocchetta 
et al. show similar findings with lower brainstem volumes in PSP and MSA compared to 
controls.177 
Another most interesting finding in our study is that the volumetric midbrain-to-pons ratio 
showed significantly lower accuracy than its planimetric counterpart. We speculate that this 
could be due to an atrophy mostly affecting the midline and hence more directly giving a lower 
midbrain-to-pons area ratio, since this measure is done at the midline on sagittal slices on the 
structural T1-weighted MRI. Further studies on local volume changes, perhaps with 
measurements of structural deformation, would be needed to elucidate this matter further. 
In our study, we find somewhat lower diagnostic accuracies when assessing the manual 
planimetric measurements compared to what some other groups have shown earlier.57,178 We 
believe that this may be due to the fact that PSP patients in our study were in relatively early 
stages of disease, considering that only 15 of 29 PSP patients had a vertical gaze palsy at the 
time of MRI. This does not mean that our PSP group is of a less certain diagnosis, since all but 
two individuals developed vertical gaze palsy during follow-up. Of the remaining two PSP 
patients, one received a diagnosis of definite PSP upon autopsy, leaving only one PSP patient 
remaining as a “possible” diagnosis at the end of the follow-up. A study by Mangesius et al. 
showed a similar tendency as our results, where a group with early PSP and parkinsonism was 
included and exhibited a lower diagnostic accuracy compared to those with later disease 
stages.179 
Another factor to take into consideration is how such an automated approach could be 
incorporated in an existing radiological infrastructure. The automated FreeSurfer-based 
segmentation itself takes many hours, compared to a few minutes for a manual planimetric 
variable. However, there could still be a potential advantage with a method that does not require 
manual labor by a radiologist and that could be run as a background process on a server and 
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deliver volumetric results as the runs are completed. Such volumetric results could then be 
included in the reports to the referring clinician. 
5.2.1 Study limitations 
There are some limitations to this study. Firstly, this is a retrospective study, and the diagnosis 
and degree of symptoms have been classified based on review of patient charts. However, the 
diagnoses have been set by specialists in neurology and the patients have been recruited 
consecutively, creating a representative clinical cohort which we believe lends it well to 
generalization to other similar populations. The patients have been subject to long-term follow-
up, which also strengthens the reliability of the respective diagnoses. 
Another point is that the patients in our cohort have been scanned using different Siemens MRI 
scanner and different acquisition protocols. There were however no significant differences 
between the groups regarding distribution across the different scanners or voxel sizes. We also 
investigated intra- and inter-scanner reliability using intraclass correlation coefficients. More 
importantly, the volumetric and planimetric measurements are inherently matched on the 
patient level since they are performed on the same structural MRI volume, so the comparisons 
between the two types of analysis are perfectly valid. 
Thirdly, the planimetric manual measurements were not performed by a radiologist, but by a 
specialist in neurology with 4 years’ experience in neuroimaging, Henrik Sjöström. Therefore, 
to assess the reliabilities in these measurements a specialist in neuroradiology, Farouk Hashim 
also performed the planimetric measurements in a randomly selected subset of 25% of the 
participants. Henrik Sjöström also re-measured this subset of subset to also allow intra-rater 
reliability assessments. Intraclass correlation coefficients were calculated and found to be 
excellent for all intra-rater reliabilities and good to excellent for the inter-rater reliabilities. 
5.2.2 Post-publication developments 
At the time of submission of this thesis from printing, the manuscript for this study is under 
review. Therefore, no new data is available for discussion. 
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5.3 STUDY IV 
In this first study on T1/T2-weighted ratio in atypical parkinsonism, we found most interesting 
differences in T1/T2-weighted ratio in the striatum, thalamus, subthalamic nucleus and the red 
nucleus in PSP compared to PD in the retrospective KIMOVE cohort. In the same cohort, we 
also found differences in the striatum between MSA and PD, and differences in the thalamus, 
subthalamic nucleus and the red nucleus between PSP and MSA.  
In the prospective BioFINDER cohort, significant differences in T1/T2-weighted ratio were 
corroborated in the subthalamic nucleus and the red nucleus in PSP compared to PD and MSA. 
There, we also found a lower ratio in the midbrain in PSP compared to the other groups. 
Although not significant at group level ANOVA analysis, we still found significantly higher 
T1/T2-weighted ratio in PD compared to healthy controls in the pairwise analysis, in line with 
earlier findings by Du et al.180 These nigral elevations in PD as well as in MSA compared to 
controls must however be interpreted with caution considering the lack of significant ANOVA. 
What causes these changes in T1/T2-weighted ratio in subcortical gray matter structures is not 
completely known. We speculate that a possible explanation for elevated T1/T2-weighted ratio 
in the red nucleus in PSP compared to the other groups could be found in Study I and Study I, 
in which higher susceptibility reflecting pathological iron accumulation in the red nucleus was 
found in PSP compared to PD and MSA. This could possibly lead to changes in the T1-weighted 
and/or T2-weighted image and thus a change in T1/T2-weighted ratio. Other factors potentially 
affecting the signal could of course be myelin content, but also considering the known 
association between neurite density and the T1/T2-weighted ratio,181 cell death as part of the 
neurodegenerative process could also contribute to such changes. 
We also assessed the diagnostic performance of the T1/T2-weighted ratio in parkinsonism. 
When using single regions as biomarkers for diagnostic separation in the KIMOVE cohort, no 
regions yielded particularly good performance. Moving on, all regions with significant 
differences in the pairwise comparisons between the groups in the KIMOVE cohort were used 
to create composite variables. When applied to the prospective BioFINDER cohort, these 
multi-region variables yielded good diagnostic performance, as measured by ROC AUC for 
PSP vs PD and PSP vs MSA, where we found AUCs of 0.82 and 0.86 respectively. 
The major strengths of Study IV are the application of the T1/T2-weighted ratio to new patient 
groups, and that the results clearly show findings that we interpret as signs of 
neurodegeneration in subcortical grey matter regions. Another strength is the use of two 
cohorts; one retrospective cohort for explorative analysis and one prospective for validation 
and testing of diagnostic performance. Interestingly, many of the substantial findings in the 
KIMOVE cohort such as the lower T1/T2-weighted ratio in the red nucleus in PSP could be 
validated in the BioFINDER cohort.  
To summarize, the results from Study IV show that there are different patterns of T1/T2-
weighted ratio in PSP compared to PD and MSA, reflecting underlying differences in 
pathology in these disorders. These differences could potentially be used as biomarkers is the 
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diagnostic process and the assessment of the parkinsonian patient. While there are currently no 
disease modifying therapies for these disorders, there is still a need for a high diagnostic 
certainty also when considering involvement in clinical trials of new medications. T1- and T2-
weighted imaging are two of the most performed sequences, and it is worth considering the 
vast amount of possible data already existing. The routine use of these acquisitions in any MRI 
examination could also simplify a possible inclusion of such a ratio method in clinical practice, 
considering that the underlying data is already acquired.  
5.3.1 Study limitations 
As in Study I and Study III, the retrospective KIMOVE cohort included patients who had 
received diagnosis of PD, PSP or MSA at Karolinska University Hospital Huddinge. In these 
patients, diagnoses and assessments of disease severity were done through review of patient 
charts. They were, however, consecutively referred for brain MRI from the neurology 
department and subjected to a long-term follow-up as part of the routine neurological care.  
The participants from the KIMOVE cohort were imaged using four different Siemens MRI 
scanners and different acquisition protocol variants. We found no differences in distributions 
of scanner model or field strength between the groups. It is also important to note that the 
construction of T1/T2-weighted ratio images involves histogram-based non-linear 
normalization to signals from bone, soft tissue and CSF. This is to allow comparison of 
combinations of different sequences and acquisition parameters. We also added an additional 
normalization step by dividing ratio levels in all regions by the mean of each individual’s white 
matter ratio values. This was to further enhance the comparability between the different 
protocol variants. 
The acquisition protocols for the T2-weighted images included a relatively high slice thickness, 
yet the resulting ratio images yielded significant results and differences between the groups 
indicating that this type of data can also be used to assess changes related to neurodegeneration. 
Another limitation common to all studies is the relatively small number of patients with PSP 
and MSA in the BioFINDER cohort. This could in part explain why some of the findings in 
the KIMOVE cohort could not be replicated in the prospective BioFINDER cohort.  
5.3.2 Post-publication developments 
At the time of submission of this thesis from printing, the manuscript for this study is under 
review. Therefore, no new data is available for discussion. 
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6 CONCLUSIONS 
 
Susceptibility mapping 
In summary, Study I and Study II, showed that susceptibility mapping techniques can be used 
to investigate disease-related changes reflecting pathological brain iron accumulation occurring 
in parkinsonian disorders.  
• The changes in susceptibility differ between the disease groups and could thus be used 
as diagnostic biomarkers, to potentially help clinicians in the separation of these 
disorders. Such separation of disorders is important in the clinical management of the 
disease and also when considering recruitment to clinical trials.  
 
• These studies have added to the growing research field and after we were able to show 
the most interesting findings of increased susceptibility in the red nucleus in PSP, other 
groups have since been able to corroborate these findings.175  
Automated brainstem volumetry 
Study III investigated the use of automated brainstem segmentation in PD, PSP and MSA, and 
compared this technique to planimetric manual measurements. 
• Automated brainstem segmentation is a promising new technique for assessing 
pathological changes in PSP. 
 
• The volume of the midbrain performed better than any of the planimetric manual 
measurements in separating PSP from PD. 
T1/T2-weighted ratio 
The results from Study IV show that T1- and T2-weighted images, commonly acquired in 
routine MRI examinations, can be combined into a T1/T2-weighted ratio which reveals 
differences between parkinsonian disorders. 
• Lower T1/T2-weighted ratio is found in the red nucleus and subthalamic nucleus in PSP. 
 
• By combining ratio values from multiple regions, a higher degree of separation of PSP 
from PD and MSA can be achieved. 
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7 FUTURE ASPECTS 
 
 
While we and others have shown that novel MRI techniques such as QSM and automated 
segmentation techniques can be used as an aid in the diagnostics in parkinsonism, there is still 
a need for further studies delving deeper into the diagnostic properties. There is also a need for 
work regarding investigation into the different subtypes of the atypical parkinsonian 
syndromes. Regarding the T1/T2-weighted ratio imaging we are, to our knowledge, the first to 
use this technique in PSP and MSA. Although we can show interesting findings with changes 
in this ratio in atypical parkinsonism, more research in needed with further analysis, validation 
and elucidation.  
Another point needing further investigation is how changes over time can be followed using 
different MRI techniques, especially in the rarer atypical parkinsonian disorders. Such 
longitudinal studies would also be necessary to better evaluate these methods’ potential as tools 
for assessing treatment effects in clinical trials. 
One of the main advantages of MRI, beside the lack of ionizing radiation and ability to visualize 
small pathological changes in tissues, is the method’s extreme versatility. With MRI, it is 
possible to image everything from the diffusion properties of water molecules to neurovascular 
coupling, to magnetic properties such as susceptibility and even electrical properties like 
conductance. In my opinion, when given a method that can measure so many different tissue 
properties in different ways, it would be reasonable to use this method in a multi-modal way to 
yield as true a picture as possible of the tissue or problem at hand. 
All in all, and probably the most important point I want to stress, I believe there is great need 
for more efforts into making new MRI techniques clinically available. This work is of course 
a vast endeavor with everything from validation and studies on reliability to cooperation with 
developers of software and systems to build working and effective pipelines for data 
managements and processing. However, if this work is not done, then the full potential of such 
promising new methods might never be reached. 
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Parkinsons sjukdom (PS) är den näst vanligaste degenerativa sjukdomen i nervsystemet, efter 
Alzheimers sjukdom. Vid PS uppstår en förlust av nervceller i övre delen av hjärnstammen, i 
ett område som heter substantia nigra, ”den svarta substansen”. Dessa nervceller producerar i 
vanliga fall en signalsubstans som heter dopamin. En minskning av dopaminnivåerna i hjärnan, 
som vid PS, kan leda till stelhet, långsamma rörelser, skakningar och nedsatt balans. Denna 
symtombild kallas för parkinsonism, och den vanligaste orsaken till parkinsonism är PS. 
Förutom dessa symtom som drabbar rörelseförmågan, så kallade motoriska symtom, är det 
vanligt med icke-motoriska symtom, såsom depression, förstoppning, nedsatt luktsinne, 
sömnstörningar och lågt blodtryck. Sådana icke-motoriska symtom kan ofta uppkomma flera 
år innan de motoriska symtomen framträder. Diagnosen PS ställs genom en klinisk bedömning 
och undersökning av neurolog men även bildundersökningar såsom skiktröntgen (DT) eller 
magnetkameraundersökning (MR) brukar utföras för att utesluta andra förklaringar till 
symtombilden. Sådana alternativa förklaringar kan till exempel vara stroke, hjärntumör eller 
multipel skleros (MS). En viktig del av omhändertagandet vid PS är även att följa och utvärdera 
effekten av insatt medicinering. Vid PS är målet att, med mediciner, ersätta effekten av det 
förlorade dopaminet; ofta genom att ge ett förstadium till dopamin, levodopa, som sedan 
omvandlas till dopamin i hjärnan.  
Förutom PS finns ett antal ovanliga sjukdomar som också brukar debutera med parkinsonism. 
Dessa sjukdomar brukar sammantaget benämnas atypisk parkinsonism. Med detta begrepp 
innefattas vanligen på fyra olika sjukdomar; progressiv supranukleär pares (PSP), multipel 
systematrofi (MSA), kortikobasal degeneration (CBD) och Lewy body-demens. Dessa 
sjukdomar kan ofta vara svåra att skilja från PS, särskilt tidigt i sjukdomsförloppet, då 
symtombilden kan vara i stort sett identisk. De orsakas dock av andra underliggande processer 
och är i grund och botten andra sjukdomar. Det som förenar framförallt PSP, MSA och CBD 
är att de ofta svarar mycket sämre på Parkinsonmediciner såsom levodopa, och att de har ett 
klart mer aggressivt förlopp med snabbare försämring och tillkomst av andra symtom som 
ögonrörelsestörningar eller blodtrycksbesvär. För att försöka skilja dessa tillstånd från PS görs 
ofta ryggmärgsvätskeprov och MR-undersökning. På MR är det välkänt att det, åtminstone i 
senare stadier av sjukdom, ibland kan finnas typiska tecken på förtvining i särskilda områden 
vilket kan stärka diagnosen. 
Syftet med denna avhandling är att undersöka nya magnetkameratekniker vid PS, PSP och 
MSA – både för att lära oss mer om dessa sjukdomar och för att ta reda på om dessa metoder 
kan användas diagnostiskt, för att skilja sjukdomarna från varandra. Att tidigt kunna skilja 
sjukdomarna från varandra är viktigt, då vård och medicinering bättre kan anpassas, och för att 
kunna ge mer sanningsenliga prognoser till patienter och anhöriga. Även vid läkemedelsstudier 
av nya potentiella bromsmediciner är det viktigt med tidiga och korrekta diagnoser. 
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Det är sedan tidigare känt att nedbrytning av nervceller kan leda till rubbningar i den lokala 
järnomsättningen. I Studie I och Studie II undersökte vi om sparade magnetkamerabilder med 
så kallad susceptibility weighted imaging (SWI) kunde vidarebehandlas för att avslöja 
skillnader i sjukdomsrelaterad järninlagring vid PS, PSP och MSA. Vi fann i dessa studier 
tydliga skillnader, där PSP uppvisade kraftig järninlagring i ett område kallat nucleus ruber, 
”den röda kärnan”. Med hjälp av dessa nivåer var det även möjligt att skilja ut patienter med 
PSP från de med PS, MSA och friska kontrollpersoner. Vi fann även tecken till ökad 
järninlagring i putamen, ”skalkärnan”, vid MSA jämfört med PS. 
I Studie III använde vi automatiska segmenteringsverktyg för att från magnetkamerabilder 
beräkna volymer av hjärnstamsdelar. Vi jämförde sedan dessa områdens diagnostiska 
egenskaper med manuella mätningar, på samma bilder, som också brukar användas vid dessa 
sjukdomar. Genom att använda volymen av övre delen av hjärnstammen, mitthjärnan, kunde 
vi urskilja patienter med PSP från de med PS eller MSA bättre än när vi använde de klassiska 
manuella måtten. Om volymen av mitthjärnan kombinerades med volymen av förlängda 
märgen förbättrades den diagnostiska förmågan att skilja de olika parkinsonismvarianterna åt 
ännu mer. 
I Studie IV studerade vi en ny metod, T1/T2-viktad kvot, och dess användbarhet vid PS och 
atypisk parkinsonism. T1/T2-viktad kvot går ut på att det räknas ut en kvot mellan två vanliga 
MR-bildtyper, och på så sätt skapas ett bättre mått på vävnadsegenskaper. Vi kunde, i den här 
studien, visa förändrad T1/T2-viktad kvot i bland annat nucleus ruber och i den subthalamiska 
kärnan i PSP jämfört med alla andra grupper. Genom att kombinera resultaten från flera olika 
områden i hjärnan kunde vi ännu bättre skilja PSP från PS och MSA. 
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